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Abstract 
Amyloidosis covers a wide range of acquired or hereditary diseases frequently 
associated to protein misfolding. The soluble proteins are abnormally deposited extra or 
intracellularly as insoluble fibrillar aggregates, inducing toxicity and causing tissue and organ 
disruption and disease. More than 30 different unrelated proteins are known to form amyloid 
fibrils in vivo under specific conditions such as abnormally high concentration levels, genetic 
mutations or folding abnormalities. Amyloidosis can be systemic, such as Familial 
Amyloidotic Polyneuropathy, or located (organ-specific), such as Alzeimer´s or Prion disease, 
which are associated with protein aggregates in the brain. 
In this work, fundamental principles of the physics of phase transitions are used to 
understand the process of amyloid fibril formation. Our strategy is to explore common aspects 
between amyloid fibrillogenesis and protein crystallization that have been identified by us 
during a pre-doctoral study. In both processes, an initial assembly of macromolecules in 
solution (nucleation step) is followed by the growth of the stable nuclei into insoluble 
supramolecular structures (growth step). Being energy-activated steps, nucleation and growth 
can be influenced by external factors such as, and most notably, the presence of additives. In 
fact, while crystallographers are challenged to obtain protein crystals for macromolecular 
structure determination, we aim at a better understanding of fibrillogenesis in order to be able 
to inhibit and not promote amyloid fibril formation. Our first goal was to characterize the 
mechanism of amyloid fibril formation by a rigorous, yet mathematically simple model that 
could be routinely used to describe protein aggregation data. Next, and following the wealth 
of published data on the clinical relevance of non-amyloidogenic aggregates, we extended our 
mathematical model to include a parallel step of off-pathway aggregation (OPA). This 
allowed us to identify a series of kinetic signatures revealing the quantitative importance of 
OPA relatively to amyloid fibrillization. We also found insoluble aggregates to produce 
solvation-in effects that decrease the thermodynamic concentration of protein in the system. 
The new theoretical tools were used on the characterization of amyloidogenesis inhibition, 
clearly distinguishing between nucleation/growth inhibitors (true inhibitors) and the pure 
thermodynamic effects caused by apparent inhibitors. An application example is included 
comprising preliminary screening tests of on/off-pathway inhibitors for α-synuclein (aSyn) 
aggregation, which is associated to Parkinson's disease. 
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This fundamental research is expected to contribute for the biophysical understanding 
of protein aggregation paving the way for development of innovative bioengineering tools for 
the therapy of neurodegenerative diseases. 
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Resumo 
As amiloidoses abrangem uma ampla gama de doenças adquiridas ou hereditárias 
associadas frequentemente com alterações conformacionais de proteínas. As proteínas 
solúveis são anormalmente depositadas no interior ou exterior das células sob a forma de 
agregados fibrilares insolúveis, os quais podem ser tóxicos e causadores de perturbações em 
tecidos e órgãos. Mais de 30 proteínas diferentes são actualmente associadas à formação de 
fibras de amilóide in vivo, sendo para isso necessárias condições específicas tais como 
concentrações anormalmente elevadas, mutações genéticas ou alterações conformacionais 
induzidas. As amiloidoses podem ser sistémicas, como a Polineuropatia Amiloidótica 
Familiar, ou localizadas em órgãos específicos tais como a doença de Alzheimer ou as 
doenças priónicas (associadas com aggregados proteicos no cérebro). 
Neste trabalho, os princípios fundamentais da física da transição de fase são usados 
para entender o processo de formação de fibras de amilóide. A nossa estratégia é explorar 
aspectos comuns entre a formação de fibras de amilóide e a cristalização de proteínas que 
identificamos durante os estudos pré-doutorais. Em ambos os processos, a associação inicial 
de um conjunto de macromoléculas em solução (passo de nucleação) é seguida pelo 
crescimento de núcleos estáveis que originam as estruturas supramoleculares insolúveis. 
Sendo os passos de nucleação e crescimento energeticamente ativados, são também 
susceptíveis de ser influenciados por factores externos, tais como, e em particular, a presença 
de aditivos. Enquanto que os cristalógrafos pretendem promover a formação de cristais de 
proteina para a determinação da estrutura macromolecular, a nossa intenção e como principal 
diferença, é que estudando em profundidade o processo de formação de fibras de amilóide 
queremos inibir a agregação. O nosso primeiro objectivo foi caracterizar o mecanismo de 
formação de fibras amilóide através de um modelo físico rigoroso, ainda que 
matematicamente simples de maneira a poder ser usado sistematicamente em ajustes de dados 
cinéticos de agregação de proteínas. A seguir, e com base num conjunto alargado de 
evidências experimentais apontando para a relevância clínica de agregados não-
amiloidogénicos, optamos por alargar o modelo matemático de forma a contemplar um passo 
adicional de agregação off-pathway (OPA). Tal permitiu-nos identificar uma série de 
assinaturas cinéticas revelando quantitativamente a importância da OPA relativamente à 
formação de fibras de amilóide. Descobrimos também que os agregados insolúveis produzem 
efeitos denominados por solvation-in, os quais diminuem a concentração termodinâmica da 
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proteína no sistema. As ferramentas teóricas desenvolvidas foram usadas na caracterização da 
inibição de formação de fibras de amilóide, ajudando a distinguir entre a inibição dos passos 
de nucleação/crescimento (através de inibidores verdadeiros) e os efeitos termodinâmicos 
causados por inibidores aparentes. Um exemplo de aplicação é apresentado envolvendo testes 
preliminares de screening de inibidores on/off-pathway da agregação da proteína α-sinucleina 
(aSyn) associada à doença de Parkinson. Espera-se que esta investigação fundamental 
contribua para a compreensão biofísica do processo de formação de fibras de amilóide e para 
o desenvolvimento de novas ferramentas de base biotecnológica na terapia de doenças 
neurodegenerativas. 
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Resumen 
Las amiloidosis cubren una amplia gama de enfermedades adquiridas o hereditarias 
causadas frecuentemente por alteraciones conformacionales de proteínas. Las proteínas 
solubles se depositan anormalmente extra o intracelularmente en forma de agregados 
fibrilares insolubles, los cuales pueden ser tóxicos y causar daños en tejidos y órganos. Más 
de 30 proteínas diferentes son actualmente asociadas a la formación de fibras de amiloide in 
vivo, bajo condiciones específicas tales como concentraciones anormalmente elevadas, 
mutaciones genéticas o alteraciones conformacionales inducidas. Las amiloidosis pueden ser 
sistémicas, como la Polineuropatia Amiloidótica Familiar, o localizadas en órganos 
específicos, tales como la enfermedad de Alzheimer o las enfermedades priónicas (asociadas 
com agregados proteicos en el cerebro). 
En este trabajo, los principios fundamentales de la física de transición de fases se 
utilizan para entender el proceso de la formación de fibras de amiloide. Nuestra estrategia es 
explorar los aspectos comunes entre la formación de fibras de amiloide y la cristalización de 
proteínas que identificamos durante estudios predoctorales. En ambos procesos, la asociación 
inicial de un conjunto de macromoléculas en solución (paso de nucleación) es seguida por el 
crecimiento de núcleos estables que originan las estructuras supramoleculares insolubles. 
Siendo los pasos de nucleación y el crecimiento energéticamente activados, son también 
susceptibles a ser influenciados por factores externos, tales como, y en particular, la presencia 
de aditivos. En quanto los cristalógrafos pretenden promover la formación de cristales de 
proteína para la determinación de su estructura macromolecular, nuestra intención y como 
principal diferencia, estudiando en profundidad el proceso de formación de fibras de amiloide 
queremos inhibir y no promover la agregación. Nuestro primer objetivo fue caracterizar el 
mecanismo de formación de fibras de amilóide a través de un modelo físico riguroso, aunque 
matemáticamente sencillo de manera a poder ser utilizado sistemáticamente para el ajuste de 
datos cinéticos de agregación de proteínas. A continuación, e con base en un amplio conjunto 
de evidencias experimentales destacando la importancia clínica de agregados no 
amilodogénicos, optamos por alargar nuestro modelo matemático de forma a contemplar un 
paso adicional de agregación off-pathway (OPA). Esto nos permitió identificar una serie de 
características cinéticas revelando la importancia quantitativa de OPA relativamente a la 
formación de fibras de amiloide. También descubrimos que los agregados insolubles 
producen efectos denominados por solvation-in, disminuyendo la concentración 
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termodinámica de la proteína en el sistema. Las herramientas teóricas desarrolladas fueron 
aplicadas a la inhibición de formación de fibras de amiloide, ayudando a distinguir la 
inhibición entre los pasos de nucleación/crecimiento (a través de inhibidores verdaderos) y los 
efectos termodinámicos causados por inhibidores aparentes. Mostramos un ejemplo de 
aplicación implicando pruebas preliminares de screening de inhibidores on/off-pathway de 
 g  g   ó     l     t í   α-sinucleína (aSyn), asociada a la enfermedad de Parkinson. Es de 
esperar que esta investigación fundamental contribuya a la comprensión biofísica del proceso 
de formación de fibras de amilóide y al desarrollo de nuevas herramientas con base 
biotecnológica para la terapia de enfermedades neurodegenerativas. 
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1.1 Common aspects in crystallogenesis and amyloid 
fibrillogenesis: the physics of the phase transition 
Many analogies have been recognized between the physical processes of protein 
crystallization and amyloid fibrillization. As protein crystals, amyloid fibrils form in the 
supersaturated solutions of precursor proteins through a nucleation and growth mechanism 
characterized by a lag phase, an initial assembly of macromolecules in solution (nucleation 
step) followed by the growth of the stable nuclei into insoluble supramolecular structures 
(growth step).The lag phase can be by-passed via seeding (seed-dependent growth)
1
. 
Protein crystals and amyloid fibrils are well organized structures stabilized by 
common molecular interactions. The size and complexity of proteins is reflected in their 
ability to form many different intermolecular contacts, specific and nonspecific: hydrogen 
bonding, electrostatic and van der Waals interactions, as well as hydrophobic interactions 
and volume excluded effects. All those interactions involved in the assembly of 
macromolecules are affected by temperature, pH, protein concentration, ionic strength of 
the solution and concentration of specific additives
2–4
. 
Being energy-activated steps, nucleation and growth can be influenced by external 
factors. Many recent studies showed that the nucleation step in protein aggregation can be 
accelerated by stirring and by using ultrasonication, previously recognized as a 
characteristic of the crystallization process
3–5
. This common dependency on ultrasonication 
can be explained for both of the processes by a common phase diagram (Figure 1.1)
4
.  
In both processes, the supersaturated protein under study (or peptide) seems to 
adopt a water-excluded ordered assembly. In those cases, supersaturation refers to a 
metastable state in which the solution keeps kinetically stable although the concentration of 
dissolved solutes is larger than the thermodynamic solubility. As a consequence of a high 
free energy barrier, in the metastable state proteins hold soluble for an extended period
3,5
. 
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Figure 1.1. Common phase diagram for protein crystallization and 
fibrillization addressing the acceleration of the nucleation step by ultrasonic 
irradiation, indicated by the red narrows. Adapted from Kitayama et al. (2013)
4
.  
 
It does not seem to be a coincidence that by the time we proposed our two-step 
mathematical model for describing amyloid aggregation kinetics in 2012
6
, and in which 
supersaturation is considered as the major driving force for protein fibrillization (common 
aspect with protein crystallization and based on our previous work
5,7
), many other studies 
confirming this evidence have appeared
1,3,4,8–13
. 
1.2. Amyloid 
Us      b t  y, th  t  m ‘ myl   ’ w s f  st    l    by R   lf V   h w    1854 t  
name a human alteration, cerebral corpora amylacea
14
. Presenting pale blue stained when 
treated with iodine and violet after the addition of sulfuric acid, Virchow declared it 
  ll l s      g v   t th    m  ‘ myl   ’. Amyl      m s f  m th  L t   t  m  myl m     
the Greek amylon
15. Th s        st     g  h    t   st   w s  ls  sh w     V   h w’s 
analysis of spleen, liver and kidney deposits, in cases of supposed amyloid A (AA) 
amyloidosis due to chronic infectious diseases. Assuming the carbohydrate rich nature of 
those tissue accumulations, they were named as amyloid deposits
16
. 
The absence of carbohydrate accumulation and high content in nitrogen was 
demonstrated in 1859 by Friedreich and Kekule, who established the proteaceous rich 
composition of amyloid deposits
15
. Even that, the nature of amyloid proteins remained 
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unclear for a long time. During the 20th century, the development of experimental 
techniques allowed to further investigations on amyloid and made possible a more precise 
description
17
.  
At the beginning, amyloid was refered to the soluble protein abnormally deposited 
extracellularly as insoluble highly ordered fibrillar aggregates, inducing toxicity and 
causing tissue and organ disruption and disease
18
. Classically recognized by their affinity 
to Congo red showing green birefringence under polarized light, those fibrillar aggregates 
were called amyloid fibrils. Later, intracellular deposition of amyloid fibrils was founded, 
missing the affinity to Congo red in most cases
19
.  
In the last decades, a key discovery happened when amyloid proteins were found to 
form amyloid fibrils in vitro. Many other proteins with no pathological role in disease and 
non-natural polypeptides have also shown to form amyloid fibrils in vitro under 
appropriate conditions
20,21
. All them presenting binding affinity to Congo red and other 
 myl    s    f    y s. I  th s    s s, th  t  m ‘ myl   -l k ’  s f  q   tly    l        
‘ myl g’ w s s gg st   wh   th     s      s  s -association14. From a more biophysical 
    t  f v  w,  t  s g     lly      t   t    m   s ‘ myl   ’   y  f th s  s    f   f b  ll   
structures independently of their nature. In this context, amyloid fibrils are defined as self-
assembled, filamentous protein or peptide aggregates with cross-β-sheet structures running 
perpendicular to the long fibril axis
22,23
, meaning they contain ribbon-like β-sheets in 
which the β-strands run perpendicular to the long fibril axis and the inter-strand hydrogen 
bonds run parallel to the long fibril axis
24
. 
Nowadays, amyloid aggregation is implicated in a wide range of scientific 
disciplines, highlighting its recent interest in biotechnology. However, extensive research 
has primarily been driven by its association with human disease
25–27
. The total number of 
proteins in the body can be estimated between 300,000 and 1 million, from the 30,000-
40,000 protein-coding genes that appear to be in the human genome
28
 and of which more 
than 30 are known to aggregate forming disease-associated amyloid fibrils
29
. Around 100 
different human pathological conditions are recognized to involve amyloid fibril 
aggregation (Table 1.1)
23,30
. 
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Table 1.1. Selected examples of polypeptides known to form disease-associated 
amyloid deposits
14,23
. 
Precusor polypeptide Amyloid classification Associated syndrome/disease 
Aβ peptide Aβ Alzh  m  ’s disease 
β2-Microglobulin A β2M Dialysis related amyloidosis 
Prion protein APrP Spongiform encephalopathies 
Prolactin APro Prolactinomas 
Transthyretin ATTR Familial amyloid polyneuropathy 
Lysozyme ALys Hereditary non-neuropathic 
systemic amyloidosis 
Serum amyloid A protein AA Rheumatoid arthritis 
Alpha-synuclein none P  k  s  ’s   s  s  
Huntingtin none H  t  gt  ’s   s  s  
Apolipoprotein AI AApoAI Atherosclerosis 
 
The fact of a wide range of different proteins/peptides forming amyloid fibrils in 
vitro has made easier further studies of amyloid aggregation. In the last decades, 
experimental and theoretical studies have been developed, disclosing many key features 
and raising a number of other new important issues that at the moment remain unclear
31
. 
1.3 Following amyloid aggregation 
A great deal of effort has been put into developing biophysical techniques for 
describing amyloid aggregation in the last decades. The identification of amyloid fibrils 
structure and oligomeric species as well as the pathway of association are crucial for a 
complete description of the process
25
. Structural information can be obtained by circular 
dichroism (CD), Fourier transform infrared spectroscopy (FTIR), size exclusion 
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chromatography (SEC), nuclear magnetic resonance (NMR) imaging
32
 and/or mass 
spectrometry
33
. Electron microscopy (EM), atomic force microscopy (AFM) and X-ray 
diffraction are frequently used to investigate intermediate oligomeric species and final 
products of aggregation
34
. 
Elucidating the molecular mechanism involved in amyloid aggregation has been 
one of the most pursued issues in order to develop anti-amyloid therapeutics. Kinetic and 
thermodynamic measurements of amyloid fibril formation are essential to achieve this 
goal. Despite the limitations of the classical methods used to follow amyloid aggregation in 
vitro, kinetic and thermodynamic data can be measured by different techniques including 
light scattering
35
, turbidity/absorbance
36
, fluorescence spectroscopy (intrinsic fluorophores 
and extrinsic dyes) and/or high-performance liquid chromatography (HPLC)
37
. More 
recently, other techniques have been developed to follow fibril growth as AFM
38,39
, total 
internal reflection fluorescence microscopy (TIRFM) and quartz crystal microbalance 
(QCM)
25,40
. Laser confocal microscopy combined with differential interference contrast 
microscopy (LCM-DIM) is an advanced microscopy technique that was originally 
developed to measure 2D nucleation kinetics of protein crystals
41
, and that represents a 
promising technique to follow the different phases during amyloid fibrillation. However, 
each method commonly reports a specific parameter of the aggregation system, such as 
mass of aggregates, monomer concentration, average filament length, etc. Complementary 
methods are often required for consistent analysis
25,26,34,42,43
.  
Covering the most commonly used methods for studying the whole amyloid 
aspects, Li et al. designed a detailed and consistent scheme (Table 1.2), useful to get a 
general idea of the current analyses outlook
38
. 
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Table 1.2. Most common biophysical methods used to study amyloid protein 
structure,amyloid aggregation, and the different assemblies involved in the process. 
Adapted from Li et al.
38
 
 Monomer Oligomer Protofibril Fibril Amyloid (in vivo) 
Atomic Structure 
Solution-state NMR  Solid-state 
NMR 
 
   X-Ray 
crystallography 
 
X-Ray absorption  
Secondary 
Structure 
Circular dichroism spectroscopy   
Fourier transform infrared spectroscopy  
  X-Ray fiber diffraction  
  Neutron scattering  
  Congo red binding/ Thioflavin S fluorescence 
   Birefringence 
  Thioflavin T fluorescence PIB/FDDNP/SB13/BF227 
Morphology 
 Transmission electron microscopy  
 Scanning transmission electron 
microscopy 
 
 Scanning tunneling microscopy  
 Atomic force microscopy  
Tertiary/quaternary 
Structure 
Electron spin resonance  
Hydrogen-Deuteriom exchange  
Limited proteolysis  
Fluorescence methodologies  
Assembly size/ Size 
distribution 
Gel electrophoresis    
PICUP    
Size-exclusion chromatography   
Analytical ultracentrifugation   
Dynamic light scattering   
IMS-MS    
 
Thioflavin-T (ThT) fluorescence spectroscopy is perhaps the most widely adopted 
technique among the entire history of the in vitro amyloid aggregation. First described in 
1959 by Vassar and Culling, the dye ThT was later characterized by Naiki et al. and 
LeVine who proof its specific interaction with the cross-β-sheet structure common to 
amyloid fibrils
44,45
. ThT molecule, formed by a benzylamine and a benzathiole ring sharing 
a carbon-carbon bond that rotates freely in solution, displays a dramatic shift of the 
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excitation and emission maximum (~440 and 482 nm respectively) upon binding of fibrils. 
ThT fluorescence originates only from the specific dye when the binding takes place by 
blocking its rings rotation
44,45
. These characteristics make from ThT a very sensitive and 
efficient reporter for real time fibrillization in solution, one of the main advantages over 
other dyes as Congo red
46
. The staining process with Congo redresults laborious, polarized 
light microscopy is required and the accurate interpretation of the apple green 
birefringence signal can be unclear
47
 
Recent advances have been developed enabling direct visualization of amyloid 
plaques in the living human brain using position emission tomography (PET) and 
radioactive tracers with higth affinity towards amyloid with the ability to cross the blood-
brain barrier (BBB)
48
 . One of the most successful radiotracers consist in a ThT derivative 
called Pittsburgh Compound-B (PIB)
49
. Much research in neurodegeneration is being 
developed for finding new amyloid ligands enabling to further studies in the in vivo 
amyloid panorama
50
. 
1.4 Fundamental models for amyloid aggregation 
Different approaches can be found in the literature to determine the kinetics and the 
mechanism of amyloid aggregation. The development of biophysical techniques that 
permit to follow the kinetics and thermodynamics of the amyloid aggregation process has 
made possible the appearance of fundamental models based on experimental data. Those 
models are our main focus in this work, but other approaches are also available, including 
empirical equations. The logistic equation has been extensively used to fit amyloid 
aggregation kinetic data. Although offering a convenient and easy option, there is no 
physical meaning behind the classic empirical equations, which cannot provide 
mechanistic information about the process
34,51
. 
Kinetic and thermodynamic descriptions of protein aggregation were recently 
reviewed by Gillam and MacPhee
34
 and previously, but also of special interest, by Morris, 
Watzky and Fink
51
. A complete and detailed overview of the available fundamental models 
historically classified as well as by their scientific base is provided in these reviews. 
The first key kinetic model for protein aggregation was proposed in 1959 by 
Oosawa et al., describing the total concentration of monomers involved in the formation of 
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helical polymers during actin fibrillization. This work and following contributions are 
based in a mechanism of primary nucleation (homogeneous nucleation) with subsequent 
monomer addition for polymerization. However, evidences of secondary growth processes 
affecting fibril formation were recognized. Ferrone et al
52
 in 1980 made a contribution to 
this type of model by introducing the concept of monomer-dependent secondary nucleation 
(heterogeneous nucleation). In contrast to homogeneous nucleation, heterogeneous 
nucleation occurs on the surface of existing fibrils and thus depend on the concentrations 
of both monomeric proteins and fibrils
53
. Oosawa et al. and Wegner and Savko introduce 
further steps of secondary growth processes as filament fragmentation and association for 
breakable amyloid filaments
51,54
. The latest contributions of this type of mechanism, and 
both of special interest are Ferrone’s (1999)55 and Knowles et al. (2009)56. 
I  1997, th  O kh m’s   z   m   m l st   2-step model was proposed by Finke and 
Watky for transition-metal nanocluster formation
57
. Later on, it was successfully applied in 
fitting a wide range of aggregating proteins, relevant in neurodegenerative disorders
51
. 
Based on a slow nucleation followed by a fast autocatalytic growth with rate constants k1 
and k2 respectively, the Finke and Watzky two-step model (F-W) is represented by the 
following scheme: 
 
Scheme 1. The Finke and Watzky mechanism
3 4
 scheme representation, where 
A represents the precatalytic form of the monomer and B corresponds to any 
catalytic form of the aggregated protein past the critical nucleus size.  
 
Rate equations to fit amyloid aggregation kinetic data are obtained by direct 
integration of this simple model. Equivalent mechanism were use to fit protein 
fibrillization by Saitô et al. in 2000, presenting a fractional form of the F-W model, and 
Murphy et al. in 2006
34,51
. 
Although most of the available models fit successfully the classical sigmoidal 
kinetic curve of protein fibrillization in which an initial lag phase is followed by 
exponential growth and a final plateau level of aggregation, there are many other common 
behaviors that remain unclear and mechanisms fail in their explanation. The growth of 
amyloid fibrils is a complex process comprising many different parallel steps and it 
becomes complicated to obtain a universal analytical solution when it is not clear which is 
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the dominant step of the process
34,51
. Evidences of the limitations of the Oosawa and  
O kh m’s   z   ty   m   ls         ly   s  ss    s w ll  s th       s st     s w th 
experimental data
34
.  
In 2012 we made a contribution by proposing a new mathematical model that 
describes successfully the kinetics of amyloid fibril formation for a wide range of different 
conditions and different amyloidogenic proteins, the Crystallization-Like Model (CLM)
6
. 
Along this work, the CLM will be presented and explained in detail. Further comparisons 
with the available models of the literature and analysis will be openly discussed. 
1.5 Therapeutic strategies targeting protein aggregation 
Over the last decades, remarkable progress has been made towards the development 
of therapeutic strategies targeting amyloidogenic diseases as a consequence of the 
important features that have been disclosed by the extensive research in protein 
aggregation
29,58
. The most promising therapeutic strategies under preclinical, clinical trials 
or clinical practice at the moment are based on the reduction of the amyloidogenic protein 
production, its stabilization, regulation of the proteostasis network and direct inhibition of 
the self-assembly process by amyloid remodeling and/or removal
29
.  
The combination of preventive strategies, acting before protein aggregation takes 
place or at an early beginning of the process, interfering with intermediate aggregates with 
strategies removing amyloid fibrils will be an encouraging option depending on the nature 
of the protein and the mechanism involved in its fibrillization. However, the mechanistic 
connection between the process of protein aggregation and tissue degeneration remains 
unclear, as well as which of the aggregate types involved in the process are toxic and their 
mechanism of cytotoxicity. A more detailed understanding of those key factors is needed 
to develop future therapies achiving successful results
29
. 
Small molecule and macromolecular approaches are currently the most promising options 
for the intervention of amyloid-associated disorders. Other approaches are adopted under 
specific conditions: in the case of amiloidogenic transthyretin (ATTR), mainly produced in 
the liver and causing TTR amyloidosis/hereditary fibrinogen amyloidosis, protein 
reduction is achieved as a standard of care by liver transplantation
29
.  
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In this work, our focus will be in inhibiting protein aggregation with small 
molecules identified via high-throughput screening. This small molecule inhibitors 
approach was initially based on early findings that demonstrated that small aromatic 
molecules such as Congo red and Thioflavin T interact specifically with amyloid fibrils 
and inhibit their formation
59,60
. Recent effort has focused on small molecule inhibitors of 
amyloid fibril formation and as a consequence, many reports have been appearing during 
the past few years
60
.  
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Summary 
Associated to neurodegenerative disorders su h  s Alzh  m  ’s, P  k  s  ’s,    
Prion diseases, the conversion of soluble proteins into amyloid fibrils remains poorly 
understood. Extensive "in vitro" measurements of protein aggregation kinetics have been 
reported but no consensus mechanism has emerged until now. This contribution aims at 
overcoming this gap by proposing a theoretically consistent Crystallization-Like Model 
(CLM) that is able to describe the classic types of amyloid fibrillization kinetics identified 
in our literature survey. Amyloid conversion represented as a function of time is shown to 
follow different curve shapes, ranging from sigmoidal to hyperbolic, according to the 
relative importance of the nucleation and growth steps. Using the CLM, apparently 
unrelated data is deconvoluted into generic mechanistic information integrating the 
combined influence of seeding, nucleation, growth and fibril breakage events. It is notable 
that this complex assembly of interdependent events is ultimately reduced to a 
mathematically simple model, whose two parameters can be determined by little more than 
visual inspection. The good fitting results obtained for all cases confirm the CLM as a 
good approximation to the generalized underlying principle governing amyloid 
fibrillization. A perspective is presented on possible applications of the CLM during the 
development of new targets for amyloid disease therapeutics. 
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2.1 Introduction 
Amyloid fibrils are insoluble ordered structures sharing a common cross -sheet 
conformation and formed by misassembly of soluble proteins and peptides
61–63
. Since these 
protein aggregates are associated with numerous neurodegenerative diseases, a great deal 
of effort has been put into understanding the mechanisms of amyloid fibril formation
51,64,65
. 
Several biophysical methods have been developed to measure the kinetics of protein 
aggregation in vitro
25,42,43,56,66
. Thioflavin-T binding fluorescence
67
 and turbidity 
measurements
36
are among the most widely adopted techniques. Despite the limitations of 
the classical methods
26
, they provide quantitative information about the mass increase of 
amyloid fibrils with time. Typically, the progress of fibrillization is expressed as the 
normalized fraction of amyloid protein converted into fibrils ()  on a mass basis,  
corresponds tothe quotient of the fibril mass increase Δm at a given instant divided by the 
total mass of fibrils formed at the end of the assay ΔmT: 
 
T
m
m




 (2.1) 
The time-course results represented in Figure 2.1 exemplify well two types of 
kinetics usually observed during amyloid fibril formation. The sigmoidal (t) trend 
obtained for 2-microglobulin (2m)
68
 (open symbols) is characteristic of nucleation-
dependent polymerization: an initial lag phase is followed by a phase of rapid growth and 
then by a stationary phase
40,69
. The hyperbolic shape obtained for transthyretin (full 
symbols) is more frequently found during seeded aggregation, i.e., when an aliquot of 
solution containing preformed fibrils is added to the amyloidogenic solution in order to 
bypass the thermodynamically unfavorable nucleation step
25,40,70
. Nevertheless, as shown 
by this example, the absence of a lag phase is also reported for unseeded reactions
70,71
. 
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Figure 2.1. Time dependent normalized fluorescence signal representing 
typical sigmoidal (open symbols) and hyperbolic (full symbols) aggregation kinetics 
of amyloid proteins during amyloidogenesis. For visual clarity, trend lines are 
represented and the time axis is normalized by the time for 95% conversi on (t95) for 
each case. Open symbols correspond to the experimental data obtained by Xue et 
al.
68
 using 61 M of  2m; t95=15.6 hr. Full symbols represent continuous 
fluorescence data from Hurshman et al.
7 0
 obtained for 0.15 mg/mL of monomeric 
transthyretin (M-TTR), which we digitized into periodic data and normalized by the 
endpoint signal; t95 = 23.4 s.  
 
Between the classical sigmoidal kinetics, showing an inflection point at 0.5i  , 
and the hyperbolic/seeded polymerization kinetics, showing no evident inflection point, 
there are a number of intermediate possibilities that have been comprehensively reviewed 
by Finke and co-workers
51,72
. As discussed in those reviews, the meaning of the different 
shapes has been interpreted over the last 50 years according to several thermodynamic and 
kinetic mechanisms. Given the complexity and variability of the protein aggregation 
models, a modular approach was recently proposed in order to systematically identify the 
mechanism that best describes nucleation (or prepolymerization), growth (or 
polymerization) and fragmentation steps
68
. The available fundamental models are in 
general highly specific for the amyloid polypeptide under study. Models containing a high 
number of parameters cannot fit to experimental data in a unique way, while some of the 
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theoretical elementary steps refer to time frames that are experimentally inaccessible. 
Overparameterization makes it hard to validate different parts of mechanistically 
elaborated model
73
, being recognized as a problem in protein aggregation modeling
74
. In 
the pursuit of a consensual, two-parameter model for describing protein aggregation 
kinetics, the 1997 Finke-Watzky (FW) mechanism for transition-metal nanocluster 
formation
57
 was successfully applied to a wide range of kinetic data
51,75
. In the formulation 
of the FW model, slow continuous nucleation is followed by autocatalytic surface growth 
so that the overall rate of protein concentration decrease is given by 
  1 2 0
d
d
C
k C k C C C
t

    (2.2) 
with k1 and k2 being, respectively, the nucleation and growth average rate constants. 
For an initial protein concentration C0, the solution of the ordinary differential equation can 
be expressed as 
 
1
0 2 0
0 1 1
2 0
2 0 2 0
1
1
1 exp 1
k
C C k C
C k k
k C t
k C k C


 
   
   
   
 (2.3) 
Note that the difference  0C C  corresponds, by mass balance, to the instantaneous 
concentration of protein aggregates
75
. The FW equation is interconvertible by algebraic 
manipulation into the Saitô's equation
32
 and into Fernández et al. equation
76
, which 
however depart from different mechanistic assumptions (see comparative study below). 
When the nucleation rates are very low (
1 0k  ), eq. 2.2 reduces to the differential form of 
the logistic function, which is commonly used to fit sigmoidal aggregation data
51,69
. 
Ferrone's equation is another example of a two-parameter protein aggregation model 
available in literature that predicts the monomer concentration to decrease with the square 
of time
55
. While avoiding overparameterization, these models are very useful from a 
practical point of view, even though some simplifying hypothesis adopted during their 
derivation may lack solid biophysical basis. For example, Saitô and co-workers, and 
Fernández et al. describe elementary kinetic steps by reaction-like rate equations that are 
first-order in relation to the fractional conversion of monomers into fibrils expressed as  
and/or 1–32,76. In an alternative formalism, Finke and Watzky consider the fibrillar state 
as the autocatalytic, polymeric form of the protein and express the elementary rate laws as 
a function of the protein concentrations in the solubilized and aggregated forms
51,72
. 
Although theoretically more appropriate, the F–W formalism results inthe paradox that, 
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according to eq. 2.2, all the dissolved protein is expected to convert into fibrils, i.e., the 
expected steady-state concentration is 0C  . This is not possible in the light of the general 
phase equilibrium condition and is not supported by measurements of dissolved protein 
concentration after long incubation times
70,77,78
. Finally, the applicability of Ferrone's 
quadratic equation is inherently limited to the early data points corresponding to ~10–20 % 
of total monomer loss
74
.  
Kinetic modeling of amyloid fibrillization reactions has also been performed using 
empirical equations such as linear and exponential decay functions
79
. As recently pointed 
out by Auer and Kashchiev while discussing the applicability of the Avrami equation
80
, it 
does not seem coincidence that such mathematically simple models are able to describe the 
(t) dependence for a wide range of polypeptides and amyloidogenic conditions. With the 
present contribution, we seek the general principle that seems to govern the kinetics of 
protein aggregation. We intend to do it in a theoretically consistent way that does not 
compromise the final simplicity of the model nor its quantitative usefulness. Infinite 
number of parameter combinations producing equally good agreement with the data should 
be avoided; that is to say, all the dynamic state variables shall be condensed in a two-
parameter model that can be uniquely fit to protein aggregation kinetics. Then, the deepest 
meaning of each constant should be possible to be determined by using different types of 
experimental data. For this mechanistic refinement to be possible, oversimplified 
hypothesis such as those identified in our literature survey should also be avoided during 
the derivation of the model. 
2.2 Crystallization-Like Model (CLM) 
Resemblances between amyloid fibril formation and protein crystallization have 
long been recognized
40,81
. Both processes involve the thermodynamic equilibrium between 
phases, an initial assembly of macromolecules into stable nuclei (nucleation step), and the 
subsequent formation of supramolecular structures by successive addition of growth units 
(growth or elongation step). We propose now to quantitatively describe the aggregation 
kinetics ofamyloid proteins using fundamental principles that are familiar to Crystal 
Growth scientists.  
2.2.1 Thermodynamic driving force 
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We will start by defining the thermodynamic driving force for amyloid fibril 
formation as the variation in chemical potential  occurring when protein molecules in a 
supersaturated amyloid solution at temperature T are transferred to a fibrillar state:  
 ln
*
a
kT
a
   (2.4) 
wherek is the Boltzmann constant, and a and a* are the activities of supersaturated 
and saturated amyloid solutions. This is analogous to the definition of supersaturation 
adopted in crystallization from solution
82
. Accurate activity coefficients are difficult to 
obtain for highly non-ideal concentrated solutions. For this reason, and for mathematical 
simplicity, we will define an approximate amyloid supersaturation  as a function of 
protein concentration C and protein solubility C*: 
 
*
*
C C
C


  (2.5) 
The protein solubility corresponds to the concentration of dissolved protein that 
equilibrates the chemical potential of the insoluble fibrillar phase. In principle, C* is 
independent of the initial protein concentration and can be obtained from the remaining 
concentration of the polypeptide in solution after long reaction times
70
. Nevertheless, when 
measuring protein aggregation in the presence of high macromolecular content 
("macromolecular crowding"), volume-excluding effects may lead to different protein 
concentrations in equilibrium
83
. We will return to this issue while discussing possible 
deviations from the CLM. The total amount of aggregates produced per unit of volume of 
solution Tm V  is given by the difference between the mass concentrations C0 and C*. 
Equation 2.5 can thus be re-written to express amyloid supersaturation as a function of the 
fraction of protein converted into amyloid aggregates () and of the initial supersaturation 
(0): 
 
 
   
0 0
0
* ( )
*
1 1
*
T
C C C C
C
m
VC

  
  
 

   
 (2.6) 
 
2.2.2 Nucleation step 
The mechanism leading to the formation of amyloid nuclei generally includes 
conformational changes of the native state
84
 and different intermediate structures such as 
polymorphous and oligomeric aggregates
85,86
, whose nature and importance varies from 
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protein to protein
51,68
. While all of the transitions involve energy barriers of different 
magnitudes, we will consider that the rate limiting step is the formation of a critical-sized 
amyloid nucleus. This postulation finds support in the well-known fact that the addition of 
preformed fibrils to amyloidogenic solutions (seeding) completely eliminates the lag phase 
and induces immediate fibril formation. Classical Nucleation Theory
87,88
, based on which 
numerous phase transition phenomena occurring in nature and technology have been 
explained
89
, will be used to estimate the frequency at which new fibrils are created. It is 
admitted that fluctuations in phase density give rise to the appearance of embryonary 
formations or nuclei that reduce the bulk free energy (due to the variation in chemical 
potential ) and increase the surface free energy (due to the creation of a fibril/solution 
interface). Above a critical nucleus size the process spontaneously evolves in the direction 
of amyloid fibril formation. Recently
88
, the following expression was proposed for the 
critical number of monomeric peptides constituting the amyloid nucleus: 
 
2
* 1n


 

 (2.7) 
where is a constant accounting for the dimensions and interfacial energies of the 
nanosized fibril. In the same work, the nucleation rate J was expressed as a complex 
function of the thermodynamic driving force for amyloid fibril formation
88
. We will adopt 
a simplified version of this relationship that takes into account the very high 
supersaturation levels associated to amyloidogenic conditions
70,77,78
. For *C C  ratios much 
higher than 10, the equilibrium concentration of fibril nuclei is expected to increase 
linearly with C, greatly simplifying the expression of J to a second-order rate equation: 
 2J A  (2.8) 
with A being a -independent kinetic factor expressed in units of frequency per 
solution volume.  
2.2.3 Growth step 
During this step, preformed fibrils grow by successive addition of new structural 
units. Due to the existence of a preliminary fibril template, the growth (or elongation) step 
is thermodynamically favored over nucleation; although both processes co-exist during the 
early phases of incubation
69
, fibril elongation is expected to become increasingly 
predominant
90
. Advanced microscopy techniques show indefinite evidences of 
unidirectional
91–94
 and bidirectional amyloid fibril growth
39,95
, reportedly involving 
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intertwining of amyloid filaments and protofibrils
96
. Whatever the mechanisms of 
assembly admitted to occur, phase transition during this step is mostly determined by a 
secondary nucleation process taking place on the surface of the protein aggregates
53,94
. 
Therefore, the elongation rate G is proportional to the frequency at which protein 
molecules leave the solution phase and reach the fibril surface. As previously stated by us 
for the case of crystal growth from solution
97–99
, the attachment probability linearly 
increases with (i) supersaturation , which drives the diffusion of molecules toward the 
interface, and with (ii) the number of energetically favorable sites for integration. The later 
quantity was found to be proportional to crystal size during crystallization
97
, and is here 
assumed to be proportional to the length of amyloid fibrils L or, more specifically, to the 
number of -sheets constituting the solid phase. We depart from a non-active binding 
mechanism, where the lateral binding of monomers is seen as a dynamic reservoir for their 
subsequent incorporation at both ends of the fibrils
100,101– Figure 2.2. We further assume 
that surface adsorption is a reversible process followed by a fast surface diffusion step, 
which is not rate-limiting while monomers are being recruited into the active sites. The 
simplified expression for the rate of fibril elongation is thus given by 
 
d
d
g
L
G k L
t
   (2.9) 
where kg is a growth rate constant accounting for the influx of amyloidogenic 
protein molecules arriving to the fibril ends, and undergoing conformational changes upon 
integration. For constant cross-section area, the mass of fibrils linearly increases with L. 
Therefore, size-dependent growth provides a phenomenological explanation for the 
autocatalytic nature of amyloid protein aggregation
69,102
, and for the semi-empirical 
evidences that the elongation rate is proportional to the mass of fibrils, directly as m-
dependent growth
74
, or indirectly as -dependent growth32 and C0–C)-dependent 
growth
51,75
. A more subtle consequence arising from eq. 2.9 is that, unless specified 
otherwise by complementary rate laws, overall elongation rates are affected by the total 
mass of fibrils present in solution but not by their number. We will return to this point 
during the derivation of the mathematical model and during the discussion of its 
limitations. 
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Figure 2.2. Schematic representation of size -dependent amyloid fibril 
growth. Monomers in solution (green rectangles) diffuse into the surface of fibrils 
where they get reversibly adsorbed (yellow rectangles) and rapidly migrate to the 
fibril ends. Accumulation of adsorbed molecules at the active sites (red arrows) 
takes place until reaching the minimal number of monomers required for integration 
and subsequent regeneration of the fibril end. For  2m, this number was estimated 
from pre-steady-state kinetic measurements  to be ~10 monomers
1 00
. Supported on 
the non-active site binding mechanism
10 0,101
, we further assume that lateral 
migration of molecules is  not rate-limiting so that the influx of monomers directly 
increases with fibril length as the attachment probability also increases. 
Accordingly, regeneration events take place faster in (A) long fibrils than in (B) 
short fibrils –  time-lapse is represented by the blackened clock symbols on the right 
side. Helical representation of amyloid fibrils adapted from
10 3
.  
 
2.2.4 Mathematical model 
Given the kinetics of nucleation and growth just defined, it is important to know 
how much and how fast amyloid fibrillization will take place. We will start by defining the 
mass of polypeptide aggregates, m, in the generic case of fibril formation using a mass of 
seeds m0 and taking into account the fibril size distribution: 
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 0
0
i i
i
m m m a n L


     (2.10) 
In the second equality, a is the cross-section area multiplied by the mass density of 
amyloid fibrils, and is assumed to not change significantly with time; ni is the number of 
fibrils with characteristic size Li. It follows that the rate at which m increases with time is 
given by 
 
0 0
d dd
d d d
i i
i i
i i
n Lm
a L a n
t t t
 
 
 
    (2.11) 
The first sum term accounts essentially for the formation of new amyloid nuclei 
containing n* molecules (eq. 2.7), which occurs at a nucleation frequency J (eq. 2.8). The 
second sum term refers to the size-dependent elongation of fibrils (eq. 2.9). Fibril 
breakage, although important for the final size distribution and for pathogenic 
proliferation
104,105
, is not expected by the CLM to influence the overall kinetics of m 
increase: on the one hand, fragmentation increases the number of fibrils but not their total 
mass; so, the first sum term of eq. 2.11 remains constant. On the other hand, provided that 
the initial mass is the same, a large number of shorter and slow growing fibrils are 
expected to have the same total mass increase per time unit as fewer and fast growing 
fibrils. This is due to the condition of size-dependent growth resulting from eq. 2.9, which 
implies that the same mass ofdifferent sized seeds will induce unvarying fibrillization 
kinetics. Experiments of amyloid fibril formation of 2m using small amounts of seeds 
apparently confirm that short, ultrasonicated fibrils induced "essentially the same kinetics" 
as less fragmented ones
106
. Nevertheless, as higher 0 fractions are used, fragmented seeds 
seem to promote the initial fibrillization rates v0
68,100
; more surprisingly, when ultrasounds 
or mechanical agitation are used during incubation, the overall conversion into amyloid 
fibrils (expressed in terms of final fluorescence intensity) is markedly affected by the type 
of agitation
107,108
. From these results, we suggest the existence of a thermodynamic rather 
than kinetic effect associated to fibril breakage. The effective concentration of protein in 
solution is likely to be influenced by the total number of monomers remaining captive on 
the fibril ends (Figure 2.2). The bigger is fibril fragmentation, the larger is the number of 
fibril ends, and more affected is the effective concentration in equilibrium. Although 
important to explain unexpected behaviors, we will not be concerned with changing 
thermodynamics due to fibril breakage and/or volume-excluding effects at this stage of the 
CLM development. Equation 2.11 is therefore re-written as a function of the kinetics of 
nucleation and growth: 
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    (2.12) 
withMw being the molecular weight of the amyloid protein and NA the Avogadro 
constant. After recognizing that the sum term corresponds to the total mass m (eq. 2.10), 
and expressing Δm and  as a function of the extent of amyloid fibril formation  (eqs. 2.1 
and 2.6) one gets 
    a b 0
d
1 1
d
k k
t

           (2.13) 
where the 0-dependent constant ka gives the magnitude of the growth step:  
 
a 0gk k   (2.14) 
andkb gives the relative nucleation-to-growth magnitude: 
 wb
A
*
* g
An M
k
N C k
  (2.15) 
An average value *n  is considered for the number of molecules constituting the 
amyloid nuclei. Although *n  increases as  (and ) decreases (eq. 2.7), the average size 
of the critical nuclei is assumed for now to be dictated by the initial supersaturation 0. In 
eq. 2.13, 0 corresponds to the mass fraction of seeds ( 0 Tm m ) and not to the initial 
amyloid conversion, which is 0 for both seeded and unseeded reactions (0) 0  . The 
analytical solution of the ordinary differential equation 2.13 subject to this initial condition 
is  
 
 b 0 a 0
0
1
1
exp 1 1 1
1
k
k t




 

      
 (2.16) 
which in the case of unseeded reactions simplifies to 
 
 b a
1
1
exp 1 1k k t
  
   
 (2.17) 
This equation is a major result of our study. Some of the practical and fundamental 
applications arising from it will now be discussed using experimental amyloid fibrillization 
kinetics obtained from the literature. Equation 2.17 will be fitted to the measured variations 
of  with time in order to determine the kinetic constants ka and kb. In so doing, the growth 
and nucleation steps will be quantitatively characterized, which is useful to design and 
predict different amyloidogenic conditions. When the rates of amyloid fibril formation are 
available for different initial protein concentrations (and for different ), further 
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fundamental insight about amyloid fibrillogenesis is gained by disclosing the meaning of 
the kinetic constants at the molecular scale. Our future work will address the cases of 
seeded fibrillization kinetics (eq 2.16) in more detail.  
2.2.5 Comparative study: Numerical fit of two-parameter models to 
experimental data on amyloid fibrillization kinetics 
Unlike what happens in protein aggregation kinetics with perfect sigmoid shape, the 
hyperbolic type of kinetics is not rate-limited by the nucleation step. Therefore, in order to 
comprehensively compare the two-parameter models listed in Table 2.1, hyperbolic protein 
aggregation curves measured by Hurshman et al.
70
 will be used. Ferrone's equation is not 
included in Table 2.1 since only a fraction of data points can be used during numerical fit 
of this model 
55,74
. 
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Table 2.1. Two-parameter models under comparison. Amyloid fibrillization 
kinetics are given by the fractional conversion of monomers into fibrils expressed 
computed as a function of time.  
Model Model Equation Comments 
CLM 
 b a
1
1
exp 1 1k k t
  
   
 
- Present work 
- Parameters: ka and kb 
Finke-Watzky
51,75
 
1
0 2 0
0 1 1
2 0
2 0 2 0
1
1
1 exp 1
k
C C k C
C k k
k C t
k C k C


 
   
   
   
 
- C0 and C are the 
initial and 
instantaneous protein 
concentration, so that
0
0
C C
C


  
- Parameters: k1 and k2 
Saitô's 
32
 
 
 
exp 1 1
exp 1 1
kt
kt

 
 
   
   
 - Parameters:  and k 
Fernández et al.
76
 
 
 
app
app
1 exp
1 exp
k t
a k t

 

 
 
- specifically derived 
for -synuclein-
polyamine complexes 
- Parameters: kapp and a 
 
Non-linear curve fit was performed using Microcal Origin 6.0 software package 
based on the Levenberg-Marquardt algorithm of 2 minimization. The fitting results are 
given in Table 2.2 in terms of standard error (SE) of fitted parameters, minimized value of 
2 and goodness of fit (R2).  
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Table 2.2. Fitting the two-parameter models listed in Table 2.1 to monomeric 
transthyretin (M-TTR) aggregation kinetics measured by Hurshman et al.
70
, 
digitized by us, and normalized by the fluorescence endpoint signals. 
CLM 
mg/mL of M-TTR 2104 R
2 ka10
3
 SE (ka)10
4
 kb SE (kb) 
0.05 12 0.981 1.1 1.8 0.66 0.16 
0.10 2.3 0.997 1.6 1.2 1.28 0.13 
0.15 3.0 0.996 1.6 1.6 1.92 0.26 
0.20 0.5 0.999 1.5 0.8 2.87 0.19 
0.25 2.3 0.996 3.0 2.9 1.73 0.24 
0.30 1.2 0.997 2.6 2.6 3.19 0.41 
0.40 2.3 0.994 3.4 5.0 3.58 0.68 
Finke-Watzky (F–W) Model 
mg/mL of M-TTR 2104 R
2 k110
3
 SE (k1)10
4
 k2C010
3
 SE (k2)10
4
 
0.05 12 0.981 0.73 0.7 0.38 2.3 
0.10 2.3 0.997 2.0 0.7 -0.47 1.7 
0.15 2.9 0.996 3.0 1.1 -1.5 2.6 
0.20 0.5 0.999 4.4 0.7 -2.9 1.4 
0.25 2.3 0.996 5.2 2.2 -2.1 4.9 
0.30 1.1 0.997 8.1 2.5 -5.4 4.9 
0.40 2.3 0.994 12 6.2 -9.0 11 
Saitô's Model 
mg/mL of M-TTR 2103 R
2  SE () k105 SE (k)104 
0.05 1.2 0.981 1.9 1 38 2.4 
0.10 0.39 0.995 37.6 181 5.0 2.3 
0.15 1.0 0.987 57.6 736 4.0 5.5 
0.20 1.3 0.981 141.6 5487 2.0 9.0 
0.25 0.68 0.989 189.3 7177 2.0 8.6 
0.30 1.8 0.959 265.7 23170 2.0 19 
0.40 2.6 0.927 318.8 43030 2.0 33 
Fernández et al. Model 
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mg/mL of M-TTR 2103 R
2 kapp10
3
 SE (kapp)10
4
 a SE (a) 
0.05 1.2 0.981 1.1 1.8 0.52 0.37 
0.10 0.47 0.994 2.0 1.8 0.09 0.15 
0.15 1.1 0.986 2.6 4.0 0.06 0.24 
0.20 1.4 0.979 3.4 6.2 0.04 0.29 
0.25 0.72 0.988 4.4 5.6 0.02 0.21 
0.30 1.9 0.958 5.7 11 0.02 0.33 
0.40 2.6 0.927 8.0 20 0.01 0.42 
 
For the sake of numerical comparison, unconstrained fit was performed for all 
models under study. In the case of the F–W model, this procedure resulted in negative 
growth rate constants (k2) which are physically unrealistic unless fibril dissolution is 
admitted. The results of Table 2.2 show that the best fitting results are obtained by the 
CLM and by the particular solution of the F–W model having no physical meaning. This is 
also illustrated in Figure 2.3, where lower values of 2 and higher values of R2 are 
associated to the CLM and to the F–W model. In addition, the parameters of these two 
models are associated to lower standard errors (Table 2.1) meaning that the quality of 
fitting is more sensitive to parameter variations.   
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Figure 2.3. Quality of fitting expressed in terms of the values of (A) 2 and 
(B) R2 for the different conditions listed in Table 2.2. Comparison between the CLM 
(○),  –W m   l (■), S  tô 's m   l () and Fernandez et al. m   l (□). R s lts 
obtained by the CLM and F–W models are superimposed.  
 
Since the equations of Saitô, Fernández et al. and FW are interconvertible by 
algebraic manipulation, the following relationships between parameters can be established: 
 1 1
2 0
k
a
k C
    (2.18) 
 app 2 0k k k C   (2.19) 
As a consequence, it is not surprising that the quality of fitting results of Saitô´s 
model and Fernández et al. model are very approximate – Figure 2.3 and Table 2.2. In the 
case of the FW model, the algorithm of 2 minimization spontaneously converged to a 
better numerical solution (although lacking physical meaning) for all but one of the 
concentrations under study. Equally good agreement with the experimental data could be 
obtained by Saitô´s model and Fernández et al. model by adopting physically unrealistic, 
negative values for each parameter. Interestingly, the best numerical fit of the three models 
corresponds in terms of 2 and R2values to the result obtained using the CLM. These 
results show that the solid biophysical basis of the CLM is also supported by better curve-
fitting results. 
 
A B 
Chapter 2: Protein aggregation described by a two-parameter model 
30 
 
2.3 Discussion 
The CLM will be tested against experimental data published by Xue et al.
68
 and 
Hurshman et al.
70
 that comprehensively describe unseeded sigmoidal and hyperbolic 
kinetics. Although different numerical methods can be applied to determine the model 
parameters ka and kb, we propose a simplified strategy that uses the time required to reach 
50% of the maximal amplitude (t50) and the aggregation rate at that instant (v50). The 
theoretical value of the product kat50 is obtained by setting 0.5   in eq. 2.17: 
 a 50
1
ln 1
b
k t
k
 
  
 
 (2.20) 
In the same way, v50 corresponds to the derivative given by eq. 2.13 for 0.5   and 
0 0  , with the product v50t50 being also a sole function of kb: 
  50 50 b
b
1 1
1 ln 1
4
v t k
k
 
   
 
 (2.21) 
As shown in Figure 2.4A, v50 is obtained from the slope of the experimental (t) 
curve at the instant t50. In a first step, the value of kb is determined from solving eq. 2.21 
using the measured values of t50 and v50. The value of ka is then determined from solving 
eq. 2.20 using t50 and the kb constant just estimated. This two-step method for determining 
the model parameters is graphically illustrated in Figure 2.4B.  
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Figure 2.4. Simplified method for determining the kinetic constants ka and kb  
from unseeded amyloid aggregation kinetics.  (A) Illustrative example for 
determining the time required to reach 50  % completion t50 (dashed lines) and the 
aggregation rate at the that instant v5 0 (solid lines) using the time dependent,  
normalized fluorescence signal measured by Xue et al.
6 8
 for 61 M of  2m; t50=15.6 
hr and v50=0.36 hr
1
. (B) The products v5 0t5 0 ( left vertical axis) and kat5 0 (right 
vertical axis) are computed as a function of kb  (log-scale) according to eqs. 2.21 and 
2.20, respectively (solid lines). From the kinetic parameters determined in (A), kb is 
firstly interpolated from the product v5 0t5 0, and then is used to interpolate the 
product kat50 from which ka is estimated (dashed arrows); kb=1.6×10
10
 and ka=1.44 
hr
1
.  
 
A 
B 
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The mechanistic similarities suggested by Fändrich
109
 when analyzing 298 amyloid 
aggregation kinetics of different polypeptides find here their underlying principle. The 
author noticed that the product of the apparent lag time t1 and the maximum aggregation 
rate vmax did not change significantly from an average value of 4.5 with standard deviation 
of 2.9 80,109. Although t1 is lower than t50, and vmax is greater or equal to v50, the product 
t1vmax is expected to be close to v50t50. The representation of eq. 2.21 in Figure 2.4B shows 
that a relatively narrow range of v50t50 values, say between 2 and 6, corresponds to kb 
values that vary many orders of magnitude, from ~10
11
 to ~10
4
. That is to say, according 
to the CLM, very different nucleation-to-growth ratios exhibited by amyloid polypeptides 
have associated nearly invariable v50t50 and t1vmax products. The bad news are that even 
small experimental errors during aggregation kinetics measurement can lead to great 
uncertainty on the estimated value of kb. The values of kb associated to thet1vmax products 
identified by Fändrich
109
 are much lower than 1, so, in eq. 2.21, 
b 1 1k   . By combining eq. 
2.20 and the simplified version of eq. 2.21 one finds that 
a 504k v  for the large number of 
amyloid aggregation kinetics analyzed. The simplified method illustrated in Figure 2.4 was 
applied to more than 200 fibrillization progress curves measured by Xue et al.
68
 at 
concentrations of 2m monomer ranging from 8 to 244 M. The selection of fitting results 
given in Figure 2.5A illustrates the good agreement obtained throughout the different 
polymerization stages and for all concentrations. 
This is especially relevant if one recalls that half-life coordinates (t50 and v50) were 
the only information used to compute the theoretical curves in their full extent. According 
to eq. 2.14, the values of ka should increase linearly with the initial supersaturation level 
0. Mean ka values of replicate experiments are represented in Figure 2.5B as a function of 
the 0 values calculated using eq. 2.5 and a C* estimation of 0.67 M for 2m under acidic 
conditions
110
.  
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Figure 2.5. Fitting the CLM to sigmoidal aggregation kinetics measured by 
Xue et al.
68
 at different 2m concentrations. (A) Theoretical kinetic curves (lines) 
are calculated using eq. 2.17 and the ka and kb constants obtained by the simplified 
method described in Figure 2.4. The selection of results covers very fast to very 
slow  2m fibrillization kinetics. (B) Influence of the initial supersaturation level 0  
on the mean ka values (symbols) determined for di fferent protein concentrations 
within a 95 % confidence interval (error bars). Solid line represents a power law 
equation with exponent 0.503.  
 
A 
B 
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The fact that the ka(0) relationship is closer to a power law function than to a linear 
function is not discouraging. On the contrary, it reflects the increasing diffusional 
limitations as the C0 increases from 8 to 244 M. More concentrated protein solutions 
result in a higher quantity of suspended fibrils, which in turn decreases the mass transfer 
rates and does not let ka to increase with 0 as fast as in diluted solutions. Concerning the 
determination of the constant kb, a great variability of results was obtained for each 2m 
concentration that was analyzed. The 95% confidence intervals for the mean kb included 
the value 0 in all cases except for C0=43.7M. The difficulty in finding statistically valid kb 
estimations confirms our concerns about the high sensitivity of this parameter, at least in 
the region of Figure 2.4B corresponding to high values of v50t50. The same uncertainty does 
not let us to conclude about the meaning of some misfit occurring when  starts to increase 
using less concentrated 2m solutions – Figure 2.5A. These discrepancies, which were not 
reproducibly observed, may represent different nucleation rates than those considered by 
the CLM or, more simply, may result from experimental baseline variations that are more 
likely to occur during slower fibrillization kinetics.  
So far we have been analyzing sigmoidal aggregation kinetics showing an initial lag 
phase that precedes the phase of rapid growth. As the nucleation step becomes not so rate-
limiting, i.e., as kb increases and v50t50 decreases, the initial lag phase becomes 
progressively shorter until no induction time is discernible. At the same time, the shape of 
the amyloid fibrillization kinetics is expected to gradually change from sigmoidal to 
hyperbolic. This is understandable from the value of amyloid fibril conversion at the 
inflection point i, which is calculated from the condition 2 2d d 0t   applied to eq. 2.13 for 
unseeded reactions ( 0 0  ): 
 
 
b
i
b
1 2
2 1
k
k




 (2.22) 
For low values of the nucleation-to-growth ratio, the progress of amyloid 
fibrillization follows a sigmoidal shape with an inflection point at 0.5i  . As kb increases, 
the sigmoid curves have their inflection at lower values of  until a stage where no 
inflection point is visible at all. This happens for 
b 0.5k   and corresponds to the hyperbolic 
aggregation kinetics. 
A good agreement between experimental and theoretical results is again observed 
in the case of hyperbolic aggregation kinetics of monomeric transthyretin (M-TTR)  
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Figure 2.6A. First estimations of ka and kb using the values of t50 and v50 were now fine-
tuned through numerical minimization of the squared error. The parameters thus obtained 
are in close agreement with those obtained using Levenberg-Marquardt algorithm of 2 
minimization  Table 2.2. Figure 2.6B shows that the obtained values of ka and kb seem to 
linearly increase with the initial supersaturation level 0calculated using eq. 2.5; a value of 
0.8 g/mL was used for the M-TTR solubility C*, which corresponds to the concentration 
of monomers in solution after 1 week of reaction time
70
. While the linear ka(0) 
relationship confirms the definition of the growth rate constant given by eq. 2.14, the 
kb(0) data suggests that, in eq. 2.15, the average number of monomers constituting the 
critical nucleus *n  increases with the initial supersaturation.  
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Figure 2.6. Fitting the CLM to hyperbolic aggregation kinetics measured by 
Hurshman et al.
70
 at different monomeric transthyretin (M -TTR) concentrations. (A) 
Symbols represent continuous fluorescence data that was digitized by us into 
periodic data and normalized by the endpoint signal. Theoretica l kinetic curves 
(lines) are calculated using eq. 2.17 and the ka and kb constants obtained by 
minimization of the squared error. (B) Influence of the initial supersaturation level 
0 on the estimated ka (open symbols) and kb constants (full symbols).  
 
This result is apparently in contradiction with the Classical Nucleation Theory 
which expects smaller critical nuclei as the thermodynamic driven force increases (eq. 2.7). 
A 
B 
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Additional statistically-reliable nucleation data is however needed before taking more 
definite conclusions about the definition of n* for amyloidogenesis. M-TTR and2m are 
amyloidogenic proteins that have rather distinct fibrillization kinetics, namely in reaction 
speed and shape of the progress curve. The ability of CLM to describe such different 
aggregation mechanisms is very encouraging. Another feature clearly distinguishing the 
two behaviors is the role of seeding on the acceleration of amyloid aggregation. While the 
addition ofpreformed aggregates of 2m has the typical effect of precluding the initial lag 
phase
68
, in the case of M-TTR the aggregation kinetics is not accelerated by seeding
70
. The 
CLM again provides the rationale for these observations based on the relative importance 
of the nucleation step relatively to growth: the very low values of kbestimated for 2m 
mean that amyloid nucleation is the rate limiting step. Therefore, the initial fibrillization 
rate v0 predicted by eq. 2.13 for 0   is also very low in the absence of seeding. Even 
small amounts of seeds may represent mass fractions 0 much higher than kb, which will 
lead to a correspondingly high increase on the value of v0 and to a change of fibrillization 
kinetics from sigmoidal to hyperbolic. On the contrary, the high values of kb obtained for 
M-TTR represent fast fibrillization rates right from the beginning of the reaction. This 
occurs independently of the values of 0 that are typically well below 1. Drastic 
differences in the value of kb may also configure different mechanisms of M-TTR and 2m 
amyloid fibril formation: amorphous M-TTR aggregates identified by microscopic 
analysis
70
 are likely act as nucleation promoters
111
. Instead, 2m fibrils had the long-
straight morphology typical of low pH, low ionic-strength conditions
68,112
, suggesting that 
elongation is the major route for fibril formation.  
At this point the CLM is confirmed as a robust two-parameter model that is able to 
describe very distinct protein aggregation kinetics and whose derivation is theoretically 
consistent and not liable to oversimplified hypothesis. As shown in Table 2.2 and Figure 
2.3, the CLM also obtained the best fitting results among the two-parameter models used to 
describe protein aggregation data that is not rate-limited by any of the steps. In a 
subsequent stage, additional mechanistic insight into the nucleation and growth steps 
should be gained by disclosing the meaning of the kinetic constants ka and kb. Our 
preliminary study on how these constants are affected by the initial supersaturation level 
seems to indicate that modifications to the Classic Nucleation Theory are needed in order 
to determine the critical size of the amyloid nucleus. Concerning the growth step, the 
condition of size-dependent growth inherent to eq.2.9 also deserves further discussion. 
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This condition is not easily tested by direct observation techniques, which are known to 
have experimental limitations such as constrained assembly on the mica/glass surface and 
growth rate dispersion
39,91–95
. An indirect, yet distinctive consequence of size-dependent 
growth is that fibrillization rates are affected by the total mass of fibrils present in solution 
but not by their number. Increased seeding efficiency obtained with fragmented (smaller) 
seed fibrils has however been observed for 2m 
68,100
 and for yeast prions
113
, which is in 
apparent contradiction with the size-dependent condition. Fibril breakage induced by 
different agitation intensities have also been reported to affect the end-point fluorescence 
signal
107,108
, which is an indication of the total amount of fibrils produced and, indirectly, 
of the protein solubility (eq. 2.6). Both type of evidences are not expected by the CLM and 
are presumably related with variations on the effective protein concentration due to volume 
excluding effects in fibril-crowded solutions. Known as an important variable in cellular 
environment, macromolecular crowding and its effects are generally associated to high 
concentrations of spectator molecules
114
. We hypothesize that the thermodynamic 
concentration of protein may also be affected in vitro by fibril breakage as an additional 
source of monomer-retaining sites. Besides providing a possible explanation for masked 
fibrillization kinetics, changing thermodynamic conditions may also be linked to a series of 
unusual behaviors reported in literature such as the effects of reaction volume
115
, 
hydrophobic surface area
116
 and surfactants
108
 on amyloid fibril formation. In all cases, not 
only the reaction rate is affected but also the reaction extent, which again supports the 
thermodynamic hypothesis of volume excluding effects taking place at the fibril-solution 
interface. Whether the effect of fibril breakage is thermodynamic or kinetic is important to 
evaluate the condition of size-dependent growth and to establish the fundamental meaning 
of constant ka: (i) is it related to probabilistic interfacial collisions and the mean life time of 
monomers at the surface of amyloid fibrils; (ii) or should it be treated as a blind kinetic 
constant such as those commonly found in protein aggregation models that consider 
reaction-like rate equations? Either way, sufficient experimental data is available 
confirming a first-order dependency of the elongation rate on the fundamental variables 
supersaturation level and fibril mass/size, which in turn leads to a first-order dependency of 
ka on the initial supersaturation level 0. 
The CLM opens new perspectives on the characterization and understanding of 
amyloid fibril kinetics. Development of new targets for amyloid disease therapeutics needs 
this model working together with other structural and molecular studies
102,117
 and 
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complemented with information on the composition of toxic nonfibrillar oligomers
86,93
. 
CLM allows to discern between the following mechanisms of inhibition: (i) protein 
solubility increase evidenced by higher values of C* in the presence of the inhibitor thus 
lowering the thermodynamic driving force for fibrillization  eq. 2.5; (ii) nucleation rates 
decrease evidenced by lower nucleation-to-growth ratios (kb) in the presence of the 
inhibitor; (iii) blocking of fibril elongation evidenced by lower kinetic constant for growth 
(ka) in the presence of inhibitor. Mechanisms that require structural interaction between 
ligand and polypeptide, such as nucleation and/or growth inhibition offer more guarantees 
to work both in vitro and in vivo. By characterizing the relative contribution of variables, 
the CLM is expected to be useful for scientific systematization during the development of 
new therapeutic strategies for amyloid diseases. 
In conclusion, we propose a quantitative Crystallization-Like Model that is able to 
describe the sigmoid and hyperbolic amyloid fibrillization kinetics commonly reported in 
literature. A simplified method is presented to determine the model parameters using 
Figure 2.4B and the measured values of the time required to reach 50% completion (t50) 
and the aggregation rate at the that instant (v50). Further insights are provided into the 
nature of critically sized amyloid nucleus, the influence of diffusive limitations and fibril 
breakage during growth, and the role of seeding as amyloid aggregation catalyst. It is 
notable that the solid biophysical basis of the CLM does not compromise its final 
simplicity. While integrating the combined influence of seeding, nucleation, growth and 
fibril breakage, eq. 2.16 is seen as a good approximation to the generalized underlying 
principle governing the kinetics of amyloid fibrillization. We expect that the CLM may be 
routinely used as a tool to characterize quantitatively and qualitatively new targets for 
amyloid disease therapeutics. 
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Summary 
Some of the most prevalent neurodegenerative diseases are characterized by the 
accumulation of amyloid fibrils in organs and tissues. While the pathogenic role of these 
fibrils is not totally established, increasing evidences suggest off-pathway aggregation 
(OPA) as a source of toxic/detoxicating deposits that still remains to be targeted. The 
present work is a step ahead towards the development of off-pathway modulators using the 
same amyloid-specific dyesas those conventionally employed to screen amyloid inhibitors. 
We identified a series ofkinetic signatures revealing the quantitative importance of OPA 
relatively to amyloid fibrillization; these include non-linear semi-log plots of amyloid 
progress curves, highly variable endpoint signals and half-life coordinates weakly 
influenced by concentration. Molecules that attenuate/intensify the magnitude of these 
signals are considered promising off-pathway inhibitors/promoters. An illustrative example 
shows that amyloid deposits of lysozyme are only the tip of an iceberg hiding a crowd of 
insoluble aggregates. Thoroughly validated using advanced microscopy techniques and 
complementary measurements of Dynamic Light Scattering (DLS), Circular Dichroism 
(CD) and soluble protein depletion, the new analytical tools are compatible with the high-
throughput methods currently employed in drug discovery.  
  
Chapter 3: How to screen amyloid off-pathway modulators 
 
44 
 
3.1 Introduction 
Nucleation and growth mechanisms are ubiquitous in nature, from atmospheric 
aerosol formation
118
 to microtubule polymerization in eukaryotic cells
119
 and 
biomineralization
120
. The present work focuses amyloid fibril formation as a particular case 
of such phase transition phenomena. Amyloid fibrils are filamentous assemblies of proteins 
in which the polypeptide backbone is arranged in a characteristic cross--sheet structure 
running perpendicular to the long axis of the fibrils. Despite the conflicting evidence about 
its pathogenic role
121
, the accumulation of amyloid deposits in a variety of organs and 
tissues is associated to the most prevalent neurodegenerative diseases and to 
amyloidosis
122
. Intermediate oligomeric species and off-pathway end-products may, 
however, be more dangerous for the development of amyloid diseases than mature fibrils 
themselves
1,121,123–125
. Conversely, the aggregation pathway might be redirected into 
insoluble oligomers less toxic than amyloid fibrils
126
, given that both types of precipitates 
kinetically compete for soluble protein
13
. As non-fibrillar species are also hard to detect, 
the molecular mechanisms involved in their formation are particularly difficult to infer
127–
129
. Their existence should, at any rate, be a disturbance to the otherwise predictable 
sigmoidal to hyperbolical kinetics of phase transition. 
By lacking the cross--sheet structure, intermediate and off-pathway species cannot 
be identified using amyloid-specific dyes such asfluorescent thioflavin-T (ThT). If solely 
amyloid-like fibrils are produced, the development of the mass-of-aggregates signal will be 
equivalent to the depletion of protein monomers in solution
34
. Both macroscopic indicators 
should be the result of "direct" phase transition events of primary (concentration-driven) 
nucleation, secondary (autocatalytic) nucleation and fibril growth (or elongation). Other 
"indirect" events, including fibril fragmentation and association, do not involve the 
transition of molecules between phases and, therefore, do not affect the reciprocity 
between aggregation of fibrils and depletion of protein. Proposed in 2012, the 
"crystallization-like model" (CLM) describes how the molecular mechanisms of nucleation 
and growth affect the evolution of amyloid conversion (  ) with time ( t ). The two-
parameter CLM equation for unseeded reactions reads
6
: 
 
 
1
1
1 1a
k t
bk e
  
 
 (3.1) 
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where 
ak , originally called the growth rate constant, is more broadly defined as the 
autocalytic rate constant since it can also include the contribution of secondary nucleation 
steps proportional to the amount of amyloid fibrils in solution. The parameter 
bk  gives the 
relative rates of primary nucleation steps over autocatalytic steps. Once demonstrated the 
ability of the CLM to describe traditional fibrillization kinetics
6
 and discriminate between 
true and apparent amyloid inhibitors
130
, new CLM-based tools are hereby proposed in 
order to identify off-pathway processes. A preliminary note is, however, required in order 
to define what are the regular kinetic behaviors expected in the absence of parallel 
aggregation. 
The current understanding of the kinetics and thermodynamics of protein 
aggregation was comprehensively reviewed by Morris, Watzky and Finke
51
, and more 
recently, by Gilliam and MacPhee
34
. The standard sigmoidal growth curve exhibiting an 
initial lag-phase followed by a period of rapid growth and a final plateau phase is, in 
general, satisfactorily fitted by the existing theoretical models, which gives rise to different 
explanations of the same result. There are, however, a number of other common behaviors 
that remain unexplained, even by the moresophisticated models
34
. Some of these 
inconsistencies are marked in red in Figure 3.1, where a graphical account of typical 
experimental results is also provided. The hyperbolic (concave) profiles exhibiting no 
inflection point or lag-phase in absence of seeding (Fig. 3.1a) are frequently reported in 
literature during the aggregation of e.g., serum albumin
131,132
, transthyretin
70,133
, 2-
microglobulin
134
, the four repeat domain of Tau
135
, apolipoprotein
136
 and amyloid- 
variants
137,138
. This kind of results is explained by the CLM as the result of predominant 
primary nucleation over the autocatalytic processes, and is also well fitted by the 
"O kh m’s R z  " m   m l st   m   l51,139. According to Oosawa-type models140 such as 
those of Ferrone et al.
55
 and Knowles et al.
56
, the early stage increase of the mass of fibrils 
cannot occur any faster than by polynomial nt  or exponential  exp kt  lawsduring unseeded 
reactions
34,141
. Therefore, Oosawa-type models fail to explain the concave profiles of the 
form  1 exp kt   shown in red in Figure 3.1A34. The CLM advantageously uses 
fundamental principles of phase transition to explain the nonlinear trends in Figure 3.1B. 
By expressing the driving force for protein aggregation as the thermodynamic 
supersaturation  * *a aC C C    (an approximation to the variation in chemical potential), 
the steady-state monomer concentration is expected to correspond to the amyloid solubility 
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*
aC C  . At the same time that the CLM was being proposed, Yoshimura et al. urged the 
need to recognize amyloidogenicity as a property determined by the monomer 
concentration relative to solubility
3
; since then, a wealth of new evidences unanimously 
confirm supersaturation as a major driving force for protein aggregation
1,8–13
. Although this 
parallel with crystallization had been hinted before
40,70
, the common practice in literature 
models is to assume the monomer concentration alone as the driving force for phase 
transition
51,55,56,139,140
 meaning that, e.g., amyloid fibrils would continue to grow until the 
solution became completely depleted from soluble protein. In addition, the duration of the 
lag-phase would be a linear function of 
0C  when represented in a log-logscale; this follows 
from model equations of variable complexity that, in general, can be simplified to a power 
law equation with a constant scaling exponent 34,142. The same does not apply for the 
CLM, where the lag-times scale exponentially with supersaturation 
0  rather than with the 
initial concentration 
0.C  The result is a "broken" curve such as those represented in Figure 
3.1B, in which the scaling factor changes its value as 
0C  decreases to values closer to 
*
aC . 
Note that although the theoretical range of concentrations includes the solubility value, the 
formation of fibrils by primary nucleation is only expected to occur for 
0C  values above a 
critical concentration higher than *.aC  The existence of breaks in lag-time versus 
concentration plots is widely reported in literature as reviewed by Eden et al.
142
. The 
different profiles simulated in Figure 3.1B result from the influence of the initial 
supersaturation 
0  on the primary nucleation rate constant bk . Both ak  and bk  influence 
the time needed to reach 50% completion (
50t ) as determined by the following equation
6
: 
 
50
1 1
ln 1
a b
t
k k
 
  
 
 (3.2) 
While the parameter 
ak  is proportional to 0 , the parameter bk  is proportional to 
the critical number of monomers constituting the amyloid nucleus 
cn , whose variation 
with 
0  is not so well established
6
. Determining the 
bk  vs. 0  relationship is particularly 
difficult owing to the amplified uncertainty associated to 
bk  estimates when sigmoidal 
aggregation curves are used
6
. Apparently in contradiction with the Classical Nucleation 
Theory, the value of 
bk  (and cn ) estimated from hyperbolic aggregation kinetics of 
transthyretin is proportional to 
0
6,70
. The inset in Figure 3.1B shows how different values 
of 
0bk   influences the scaling exponent  extracted for high monomer concentrations. 
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Sufficiently low 
0bk   values are chosen in order to assure meaningful durations of the 
lag-phase. Although other scaling behaviors result from admitting different  0bk   
functions, the interval of  valueslying between 2 and 1 is in good agreement with recent 
Monte Carlo simulations that extend the classical nucleation-elongation-fragmentation 
scheme to include a stochastic nucleation step
142
. Each of the closed-form solutions of 
Oosawa-type models predicts a different scaling exponent that remains approximately 
constant over the concentration range
34,143
; explaining the existence of broken curves was 
shown to require additional fundamental insights besides the simple interplay between the 
different mechanistic alternatives
142,144. I  O kh m’s R z  -type models, sigmoidal 
aggregation curves exhibiting pronounced lag-phases correspond to the limit case of very 
low primary nucleation rates for which the model equations simplify to a logistic function
6
. 
Here again, the exponential factor  is approximately constant (close to 1) over the 
concentration ranges that produce lag-phases. A striking result not covered by any of the 
scenarios in Figure 3.1B is the weak dependence of the lag-time on concentration with 
absolute values of  well below 1 at high monomer concentrations34,56,142,145. In the case of 
lysozyme aggregation under harsh denaturating conditions the process becomes nearly 
concentration independent (≃ 0) for protein concentrations significantly higher than the 
solubility
142
. The formation of intermediate and off-pathway species is a likely explanation 
of this and of other deviations from canonical kinetics as illustrated next for HEWL 
aggregation under conditions of low pH (1.6) and high temperature (60 ºC) known to 
produce other aggregates than amyloid fibrils
146–148
. 
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Figure 3.1. Canonical kinetic profiles expected by the CLM (green and red) 
but not expected by other theoretical mo dels (red). (A) Hyperbolic to sigmoidal 
protein aggregation curves are obtained from Eq. 1 as the relative magnitude of 
primary nucleation decreases from kb=10 to 10
-6
 ( log-scale color bar). Inset: the  kat  
timescale is expanded to show complete sigmoidal growth curves. The hyperbolic 
profiles marked in red are not expected for unseeded reactions by Oosawa -type 
models
55,56 , 140
.  (B) log-log representation of  t50 (an indicator of the duration of the 
lag phase) as a function of the protein concentration computed using Eq. 2 for 
different values of kb/0. The slope of the dashed line corresponds to the exponential 
scaling factor  ( illustrative example for high protein concentrations and 
kb/0=10
2
).  The broken curves shown in red are not expected by the different 
closed-form solutions of Oosawa-ty       O kh m’s R z  -type models. Inset: in 
the absence of off-pathway processes, the absolute value of  is comprised between 1 
and 2 according to the value of  kb.  
A 
B 
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3.2 Experimental Procedures 
Chemicals: 
HEWLwas obtained from Merk KGaA (Darmstadt, Germany). ThT was obtained 
from Sigma-Aldrich (St Louis, MO, USA) and used as received. Other chemicals were 
reagent grade and obtained from Merk KGaA (Darmstadt, Germany). 
HEWL preparation: 
HEWL powder was dissolved in 25 mM HCl pH 1.6 and dialyzed against 25 mM 
HCl, pH 1.6, using a cut-off 3500 Da membrane (Spectrum, Fisher Scientific). The 
concentration of the dialyzed protein solution was determined by absorbance 
measurements at 280 nm using an extinction coefficient of 37752 M
-1
cm
-1
. Protein stocks 
were stored at 4 ºC for no longer than one week. 
ThT Fluorescence: 
ThT fluorescence kinetic measurements were carried out at 60 ºC in 96-well plates 
(Thermo Scientific, microtiter) in a CHAMELEON 
TM
V Microplate Reader (Hidex Co., 
Turku, Finland) at an excitation wavelength of 440 nm and an emission wavelength of 485 
nm. ThT stock solution was prepared by dissolving the dried powder in 25 mM HCl, pH 
1.6, and filtered through a sterile 0.45 μm pore size PES membrane filter (Jet Biofil). The 
concentration was determined by absorbance measurements at 411 nm using an extinction 
coefficient of 22000 1 1M cm  . Samples of 120 μl with a final ThT concentration of 2.8 mM 
and HEWL concentrations of 0.60, 0.93, 1.25, 1.39 and 1.76 mM were sealed with 100 μl 
of paraffin oil. Measurements were recorded every 1800 s, after sample homogenization by 
300s shaking. Data was background-corrected for the ThT fluorescence of the respective 
solvent in the absence of protein. 
Depletion of soluble HEWL: 
Independent 1.76 mM HEWL samples were incubated at 60 ºC and periodically 
filtered through a sterile 0.22 μm pore size PES membrane filter (Jet Biofil). After 1 hour 
at room temperature, filtered samples were diluted 1:50 in 25 mM HCl pH 1.6 and 
analyzed spectrophotometrically at 280 nm using a 1 cm pathlength quartz cuvette (Hellma 
GmbH & Co.KG, Müllheim, Germany) and an extinction coefficient of 37752 1 1M cm  . 
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CD: 
CD experiments were performed using a Jasco J-815 spectropolarimeter (Tokyo, 
Japan) equipped with a Peltier-controlled thermostated cell support. Independent 1.76 mM 
HEWL samples were incubated at 60 ºC for periods of 1 to 7 days. Samples,were diluted 
1:400 in 25 mM HCl, pH 1.6. CD spectra were measured from 190 to 260 nm in a 0.1 cm 
pathlength quartz cuvette (Hellma Analytics). The final spectrum of all samples was an 
average of 16 independent scans recorded with 1 nm bandwidth, 2s digital integration time 
and a scanning speed of 50 nm/min. 
DLS: 
DLS measurements were performed at 25 ºC using an ALV/DLS/ SLS-5000F, SP-
86 goniometer system (ALV-GmbH, Langen, Germany) equipped with a CW diode-
pumpedNd:YAG solid-state Compass-DPSS laser with a symmetrizer (Coherent Inc., 
Santa Clara, CA). The laser operates at 532 nm with an output power of 400 mW. The 
intensity scale was calibrated against scattering from toluene. Independent 1.76 mM 
HEWL samples incubated at 60 ºC for periods of 1 to 7 days were analyzed at least three 
times. Measurements were made at a scattering angle 90º to the incident beam for 5-10 
min. 
AFM: 
Independent 1.76 mM HEWL samples incubated at 60 ºC for 0, 1, 2, 3, 4 and 7 
days were diluted 1:400 in 25 mM HCl, pH 1.6. Samples were spin-coated onto silicon 
wafers and dried in vacuum conditions for 4-5 hours. AFM images were recorded in non-
contact mode using an AFM, JEOL instrument (JSPM 4210) equipped with a nitride 
cantilever NSC15 from MicroMasch, USA. Typical working frequency and spring 
constant: 325 kHz and 40 N/m, respectively. Topography images were recorded adapting 
the offset point according to the roughness of each sample. 
TEM: 
Independent 1.76 mM HEWL samples were incubated at 60 ºC for periods of 1 to 7 
days. Sample solutions were applied onto a carbon–formvar coated 200–400 mesh spacing 
grids. After 1 minute, excess sample solution was removed by blotting with filter paper and 
stained with filtered aqueous solution of 2% uranyl acetate (for 45 seconds). Grids were 
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examined under a JEOL JEM 1400 TEM (Tokyo, Japan) operated at 80 kV. Images were 
digitally recorded using a Gatan SC 1000 ORIUS CCD camera (Warrendale, PA, USA). 
Mathematical Model Derivation: 
In the presence of off-pathway aggregation, the increase of total aggregates in 
solution is due to the formation of either amyloid fibrils or off-pathway aggregates: 
 
offa
dmdmdm
dt dt dt
   (3.3) 
While the formerprocess is described by the two-parameter CLM
6
,the latter is here 
characterized by a off-pathway nucleation step, which, similar to amyloid nucleation, is 
considered to be second-order in relation to supersaturation: 
 * 2
off
off off
dm
k V
dt
  (3.4) 
The rate constant *
offk  is the nucleation frequency expressed per volume of solution (
V ). Since the two types of aggregates in question have distinct structural organizations, the 
concentration of soluble protein equilibrating the solid phase is also different, i.e., 
supersaturation has to be differently defined as a function of the protein solubility *
iC  for 
amyloid fibrils (subscript i a ) and for off-pathway aggregates (subscript i off ): 
 
*
*
i
i
i
C C
C


  (3.5) 
As the formation of total aggregates and the depletion of soluble protein are 
complementary processes, m  is proportional to the difference  0C C  and i  is 
alternatively expressed as 
 
0,1i i
i
m
M
 
 
  
 
 (3.6) 
where
iM is the total amount of species i(either a or off) that would be produced in 
the absence of the other species (either off or a), and 
0,i  is the initial supersaturation i 
evaluated according to eq. 3.5both
iM  and 0,i  are proportional to the difference  *0 iC C
. Accordingly, eq. 3.4 is rewritten as 
 
2
* 2
0, 1
off
off off
off
dm m
k V
dt M

 
   
 
 (3.7) 
whereas the differential form of the CLM equation
6
, 
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0, 0,
d
d
a a a
a b a
a a
k k
t
  

 
 
   
 
 (3.8) 
is rewritten as 
 
d
1 1
d
a
a b a
a a
m m
k k
t M M


    
        
    
 (3.9) 
where
ak is defined as the autocalytic rate constant and bk  gives the relative rates of 
primary nucleation steps over autocatalytic steps. The amyloid conversion is normalized as 
a a am M   thus implying that the final value of 1 is only reached when no off-pathway 
aggregates are formed. In all other occasions the final value of 
a  represents the fraction of 
amyloid fibrils produced in relation to that expected in the absence of a competitive 
process. In our simulations amyloid fibrils are not supposed to dissolve once the protein 
concentration decreases below the solubility value *
aC . After that limit, the amyloid 
supersaturation 
a  is considered 0. By adopting normalized units of time ( )ak t   and of 
total amount of aggregates 
0( )m M   on eq, 3.9 results:  
 0 0
d
1 1
d
a
b a
a a
M M
k
M M

  

    
        
    
 (3.10) 
Finally, the same procedure is applied to eq 3.4, which is then replaced in eq. 3.3 to 
obtain 
 
0 0
0
2
0
d
1 1
d
1
a
b a
a a
off
off
M M M
k
M M M
M
k
M

  


    
         
    
 
   
 
 (3.11) 
where offk  is the normalized rate constant for off-pathway aggregation, 
 
* 2
0,
0
off off
off
a
k V
k
k M

  (3.12) 
and 
0M  is the final amount of total aggregates. Being proportional to 0C  minus the 
final concentration of soluble protein (either *
aC  or 
*
offC ), 0M  also corresponds to either aM  
or offM  depending on which species  amyloid fibrils or off-pathway aggregates  dictates 
the equilibrium. 
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The system of ordinary differential equations formed by eqs. 3.10 and 3.11 was 
solved using Matlabsubject to the initial conditions  0 0a   and  0 0  ,and 
according to the details given in each of the following numerical simulations. 
Simulation 1Effect of the off-pathway rate constant offk on the aggregation 
kinetics: 
We have solved eqs. 3.10 and 3.11 for different combinations of parameters 
bk  and 
offk . The used value of 0 aM M  was estimated based on measurements of 
*
aC  1.50 mM 
and *
offC  0.75 mM obtained during protein depletion experiments carried out at 0C  1.76 
mM: 
 
*
00
*
0
off
a a
C CM
M C C



 (3.13) 
Since off-pathway aggregates have the lowest solubility, the final amount of total 
aggregates 
0M  is calculated using 
*
offC  as the equilibrium protein concentration and 
0 1offM M  .  
Simulation 2Effect of the initial protein concentration 
0C  on the aggregation 
kinetics: 
Equations 3.10 and 3.11 were also solved taking into account 
0C -dependent 
variables 
0 aM M  (eq. 13), bk  (proportional to 0,a ) and offk , whose definition can be 
rewritten as 
 
*
0,
0,
off off
off
w a
k
k
M

 
 
   
 
 (3.14) 
obtained after replacing in eq. 3.12 (i) the direct dependence of 
ak  on 0,a , 
 
0.a ak   (3.15) 
and (ii) the definition of
0M , 
  *0 0 off wM C C M V   (3.16) 
with 
wM  being the molecular weight of the amyloidogenic protein.From the 
obtained  a   progress curves we computed the corresponding     curves following 
the definitions given in Simulation 1. The theoretical half-life coordinates 
50t  and 50v  were 
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respectively obtained from the normalized time required to reach 50% conversion 
50  and 
from slope d d   at the same instant: 
 5050
0,a
t


  (3.17) 
 50 0,
50
d
d
av



  (3.18) 
As arbitrary units of time and aggregation rate are used, an arbitrary value of   is 
also considered. The influence of 
0C  on 0,a  and 0,off  in eqs.3.14, 3.17 and 3.18 is given 
in eq. 3.5. Different solutions were obtained for different values of 
0C , 0,b ak   and 
0, 0,off a offk   . 
3.3 Results 
The amyloid fibrillization curves of HEWL suggest OPA: 
The comparative analysis made in Introduction indicates that the CLM can be used 
as a touchstone to identify andcharacterize unconventional aggregation kinetics. This is 
now illustrated using in vitro experimental data measured by us during the aggregation of 
HEWL under conditions of low pH (1.6), high temperature (60 ºC) and high HEWL 
      t  t    (≥ 0.60 mM)   q      t           myl    f b  ls w th  t           t    ts 
or salts. Representing the results as the normalized intensity of ThT fluorescence with time 
(Fig. 3.2a) and by the concentration-dependent half-life coordinates (Figs. 3.2b and 3.2c) 
does not seem to indicate especially unusual kinetics, except the weak concentration 
dependence of 
50t  (Fig. 3.2b) and 50v  (Fig. 3.2c). Characteristic but not exclusive of 
HEWL aggregation, the low reproducibility of the results further prevents definitive 
conclusions to be taken without testing wider ranges of protein concentrations and 
numerous other replicates
142,145,149,150
. The previously reported formation of intermediate 
and off-pathway species during amyloid fibrillization of lysozyme should however produce 
atypical kinetic signatures and explain in part the poor reproducibility indexes. Parallel 
phase transition processes, such us the formation of insoluble oligomers and protein 
precipitates, acts as a sink of the soluble amyloid pool thus affecting the rate at which 
amyloid fibrils are formed and their final amount. Since the non-amyloidogenic pathways 
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also involve stochastic nucleation steps, their presence is expected to increase the overall 
variability of the results. 
 
Figure 3.2. Influence of the initial protein concentration on the kinetics of 
amyloid fibril formation of HEWL at pH 1.6 and 60 ºC. (A) ThT fluorescence 
A 
B 
C 
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increase during the aggregation of 0.60 mM (blue), 0.93 mM (light blue), 1.25 mM 
(green), 1.39 mM (orange) and 1.76 mM (red) HEWL represented in normalized 
units as a function of the incubation time. (B,C) Influence of the initial HEWL 
concentration (B) on the time required to reach 50  % completion ( t5 0) and (C) on the 
aggregation rate at the same instant (ν50).  Log-log and linear-linear scales are 
adopted in (B) and (C), respectively; symbols and error bars represent mean values 
and standard deviations. (B) The linear fit (solid line) indicates an exponential 
scaling factor  of 0.24.  
 
The impact of an additional source of monomer depletion besides primary 
nucleation, secondary nucleation and fibril elongation was investigated within the CLM 
framework by introducing an off-pathway nucleation step, which, similar to amyloid 
nucleation, is considered to be second-order in relation to supersaturation. From this 
theoretical exercise, which is described in detail in Experimental Procedures, we found 
practical ways to identify supplementary kinetic steps from a single aggregation curve 
(Figs. 3.3 and 3.4); as shown in Figure 3.3A, the conventional hyperbolic/sigmoidal curves 
previously represented in Figure 3.1A are expected to show a noticeable linear phase when 
amyloid conversion is expressed as  1   and represented as a function of time in a 
log-linear scale. Note that  1   corresponds to the mass of fibrilsalready produced 
divided by the mass of fibrils still to be formed. The linear phase starts after elapsed a 
period of time of ≃ 1
ak
  and lasts until the end of the reaction. In the case of sigmoidal 
curves (low 
bk  values in Fig. 3.3A), this interval should include the whole fast growth 
period. As a first fingerprint of the presence of off-pathway species, a disturbance to the 
linear profile is shown in Figure 3.3B with the initial concave phase being prolonged until 
later stages of amyloid fibril formation. As the amyloid reaction approaches completion, 
the concave phase is immediately succeeded by a convex phase, whose presence might be 
difficult to identify in practice due to the increased signal noise of  1   data. As 
Figures 3.4E and 3.4F also show, the deviations from linearity result from the existence of 
a parallel nucleation step characterized by the rate constant 
offk . Representing the measured 
HEWL aggregation curves in the modified coordinates consistently show nonlinear 
concave trends during the fast growth stages - Figure 3.3C. Owing to fluorescence noise 
amplification, the initial and final reaction stages are omitted in Figure 3.3C. Log-linear 
representations of the measured  1   with the incubation time are a new probe for the 
presence of off-pathway aggregates with facile implementation during high-throughput 
inhibitor screenings. However, and as discussed next, the information provided by 
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representations such as Figure 3.3C is essentially qualitative and requires additional scaling 
studies in order to be consolidated. 
 
Figure 3.3. Kinetic signatures suggesting the pre sence of off-pathway 
species.  (A) The typical CLM aggregation curves in Figure 3.1 (without OPA) are 
represented in modified log-linear coordinates relating α/(1-α)  vs.  dimensionless 
A 
B 
C 
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time (same color code as in Fig. 3.1A). Linear relationships are observed for kat˃1 
(after the lag phases in Fig. 1a are surpassed). (B) Effects provoked by other phase 
transition processes besides the nucleation and growth of amyloid fibrils. The linear 
phase rapidly vanishes in the presence of parallel nucleation events characteriz ed by 
the rate constant  kof f. Numerical results obtained from Simulation 1 (Experimental 
Procedures), using kb=10
2
 and the values of kof f indicated in the color bar. Dashed 
lines in (A) and (B) correspond to the same result. (C) The measured aggregation 
curves of HEWL in Figure 3.2A are represented in the modified coordinates (same 
color code as in Fig. 3.2A). The concave phase prolonged until amyloid conversions 
close to 1 suggest the existence of OPA.  
 
Ideal curves with marked linear phases as in Figure 3.3A do not necessarily mean 
the absence of supplementary pathways, which might take place at much slower rates than 
amyloid fibrillization. On the other hand, prolonged concave phases eventually followed 
by a convex phase (Figs. 3.3B, 3.3C, and Figs. 3.4E and 3.4F) are a necessary but not 
sufficient condition for the existence of parallel phase transition processes, seeing that 
similar outcomes might be produced by other phenomena, e.g., fluorescence quenching. 
The results obtained from Simulation 1 (Experimental Procedures) and represented in 
Figures 3.4A and 3.4B suggest additional evidences based on the variability of the 
endpoint signals F . In principle, these thermodynamically-determined measurements 
should be highly reproducible since they are not subject to stochastic contingencies as, for 
example, the nucleation steps.Figures 3.4A and 3.4B show, however, that the endpoint 
signals are expected to change as different values of 
bk  and offk  are considered. This is 
understandable in view of the existing competition between amyloid and off-pathway 
nucleation: the faster is one process relatively to the other, the larger is its share of the total 
soluble protein. In turn, if no OPA takes place, it does not matter thermodynamically 
whether amyloid formation is fast or slow, reproducible or changeable, because the value 
of F  is mainly determined by the  *0 aC C  difference. The experimental results 
previously shown in Figure 3.2A are associated to highly variable end-point fluorescence 
signals (data not shown). Such low reproducibility is normally associated to the nucleation 
rate constant 
bk  due to the exponentiation of the lag-time variability
6
. The propagation of 
the kinetic uncertainty to the F  values can be justified by the occurrence of parallel 
nucleation processes, both characterized by fluctuating rate constants (
bk and offk ). 
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Figure 3.4. Numerical solutions of the extended CLM accounting off -
pathway aggregation. Equation 3.10 was solved as described in Simulation 1 using 
kb=10
1
 ( left panel) and kb=10
7
 (right panel) and the values of kof f   given in the right 
side color bar.  Results are expressed as the variation with the normalized time ka t of 
(A, B) the predicted amyloid fluorescence signal  F/Fa (equivalent to  αa),  (C, D) the 
amyloid conversion  α , (E, F)  the modified amyloid conversion  α/(1-α)  in log-linear 
scale and (G, H) the dimensionless amount of total aggregates  m/M0.  
 
OPA Scaling Laws: 
After having scrutinized the progress curves of HEWL aggregation subject to 
different types of normalization and having analyzed the variability of the endpoint 
fluorescence signal, it remains to be discussed the peculiar scaling laws of 
50t  and 50v  with 
A B 
C D 
E F 
G H 
Chapter 3: How to screen amyloid off-pathway modulators 
 
60 
 
protein concentration. In fact, the exponent  determined from the results in Figure 3.2B, 
and the aggregation rate data represented in Figure 2C are indicative of abnormally weak 
influence of 
0C  on the two half-life coordinates. When only amyloid fibrils are formed, 
minimum values of ||≃1 are predicted by the CLM under conditions of low nucleation 
rates (Fig. 3.1b), for which 
50v  also reduces to ≃ 4 ak , a linear function of 0C
6
. The 
measured relationships shown in Figures 3.2B and 3.2C are unexpected not only by the 2-
parameter CLM as by any other current model (see discussion of Fig. 3.1). Once again a 
solution to this problem seems possible by extending CLM to account the formation of 
non-amyloidogenic precipitates. The altered role of the initial protein concentration is 
studied in Simulation 2 (Experimental Procedures), with Figure 3.5 showing the numerical 
solutions assuming predominant OPA ( b offk k ≪1). Figure 3.5A shows that the duration of 
the lag phase hardly changes with the protein concentration(≃ 0) and that 
50t  may even 
increase with 
0C  (> 0). This apparently contradictory result is explained by the presence 
of a competitive off-pathway step that is comparatively more favored by higher
0C  values 
than the amyloid aggregation step. Equally, Figure 3.5B shows that the amyloid 
aggregation rate 
50v  can be weakly influenced by 0C  or even decrease as 0C  increases. To 
be observed, these paradoxical kinetic results require high values of offk  in order that the 
considered range of protein concentration is above the critical limit for amyloid formation. 
Figure 3.5 also shows sudden variations of the 
50 0( )t C  and 50 0( )v C  scaling factors taking 
place along narrow ranges of 
0C  values. In agreement with estimations of  taken from 
literature
142
, the broken curves are not confined to protein concentrations close to the 
amylois solubility (as in Fig. 3.1b) but can be observed for *
0 a
C C  values ≫1. Our selection 
of 
bk  and offk  values in Figure 3.5 places the region of weak 0C  dependencies in the same 
*
0 a
C C  range as that used during the HEWL aggregation experiments. While reconciling 
the results of Figures 3.2B and 3.2C with the theory of protein aggregation, this agreement 
is the first step towards a univocal, all-inclusive validation of the model of which the 
following section presents a numerical attempt. 
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Figure 3.5. Influence of the protein concentration on the half -life coordinates 
when OPA is predominant. Solutions of the extended CLM calculated for kb /0 =10
- 6
 
given as (A) the log-log representation of t50 as a  function of the C0/Ca* ratio and  
(B) the variation of ν50  with C0 /Ca* .  (A ,B)  Different colors mean different C0-
independent kof f   values as indicated by  the color bar in the right side. Numerical 
details given in Simulation 2 (Experimental Procedures) .  
 
Protein depletion confirms OPA prevalence: 
At this point, we have accumulated a set of evidences suggesting that amyloid 
fibrils are only the tip of an iceberg hiding a crowd of ThT-invisible aggregates. Although 
independent from each other, these evidences stem, in all cases, from conventional ThT 
fluorescence measurements. The first estimations of 
bk  values ~10
7
, indicate that the 
amyloid nucleation is many order of magnitudes slower than the autocatalytic steps. On the 
other hand, offk  values comprised between ~10
2
 and ~10
1
 configure a case where off-
pathway species are produced at much higher ratesthan amyloid fibrils. These conclusions 
were further tested by complementary techniques, namely, by checking whether the 
A 
B 
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depletion of protein from solution matches the observed kinetics of amyloid fibril 
formation (Figs. 3.6a and 3.6b). By changing the focus from the amyloid fibrils to the 
dissolved protein we also wanted to measure the equilibrium concentration for long 
reaction times as an estimation of the thermodynamic solubility. Independent HEWL 
samples incubated at the same conditions of pH and temperature as during the fluorimetric 
assays were periodically filtered and analyzed spectrophotometrically at 280 nm (see 
Materials and Methods). The results in Figure 3.6A show that solute depletion starts 
immediately after incubation, i.e., before the formation of any detectable amount of 
amyloid fibrils (Fig. 3.6B); moreover, phase transition processes continue to occur many 
days after the plateau in fluorescence emission is reached. Besides confirming the 
predominance of OPA, these results also indicate that HEWL amyloid fibrils equilibrate 
with the solution earlier, and at higher protein concentration, than the other aggregates. The 
simulated curves in Figure 3.6A were computed using the estimates of 
bk  and offk  that 
followed from ThT fluorescence kinetic analysis and using the values of amyloid solubility 
( *
aC ) and off-pathway solubility (
*
offC ) of 1.50 mM and 0.75 mM corresponding to 
estimations of HEWL concentration after ~90 h and ≫1000 h incubation, respectively. The 
calculated dimensionless time needed to obtain the same total conversion as after 700 h 
incubation was 100ak t  , from which the value of 1 7ak   h
1
 was determined. The good 
agreement between simulated and measured results reported in Figure 3.6A was achieved 
using a relatively narrow range of offk  values (color bar), meaning that the expectable 
variability of this parameter is able to explain the observed scattering of the measured 
profile. Despite all the converging evidences, the set of values chosen for 
ak , bk  and offk  
should be taken as approximate guesses rather than as definitive results. This is because the 
adopted equilibrium concentrations for amyloid ( *
aC ) and off-pathway (
*
offC )aggregates are 
expected to differ substantially from the real thermodynamic solubilities. Not only the 
solutions are highly concentrated and nonideal, but also the chemical potential of the solute 
seems to be drastically influenced by the presence of aggregates in a process akin to 
volume exclusion effects
151
. The asymptotic HEWL concentration of 0.75 mM estimated 
for long reaction times implies that aggregation assays conducted at concentrations below 
this limit would not produce off-pathway precipitates, let alone amyloid fibrils. Yet, as the 
results in Figure 3.2 demonstrate, HEWL concentrations as low as 0.60 mM continue to 
produce aggregates that stain positive for ThT. The thermodynamic concentration of 
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dissolved protein seems to be decreased by the presence of aggregates, which, combined 
with changes in solution viscosity may explain why the phase transition processes cease at 
high HEWL concentrations and high content of total aggregates. These effects, to be 
discussed in detail elsewhere, imply a faster supersaturation decrease than that considered 
in our model. Therefore, they should also account for the differences observed in Figure 
3.6B where the measured aggregation curves move faster towards equilibrium than the 
expected by the extended CLM for the selected set of parameters. Using real protein 
concentrations in our theoretical simulations would require time-evolving activity 
coefficients that are not available right now. 
Complementary structural, morphological and size-distribution data: 
The changes in the secondary structure of HEWL were followed by recording the 
far-UV spectra along the different phases of the aggregation process (Fig. 3.6c). The far-
UV spectrum of non-incubated HEWL shows the 208 nm and 222 nm bands characteristic 
of the α-helical structure of the native protein152. Upon the first day of incubation, the 
ellipticity strongly decreases and the minimum CD intensity takes place at slightly lower 
wavelengths. The same tendency is observed until day 4, yet with smaller variations of 
CD. These results indicate the formation of pre-amyloid structures, presumably amorphous 
aggregates, which are less helical than the initial conformation. The formation of ThT-
positive aggregates after the first day of incubation (Fig. 3.6b) did not provoke the position 
of minimum CD to clearly deviate from ~208 nm to ~215220 nm as expected for -sheet 
structures. Therefore, and as suggested by the protein depletion results, amorphous 
aggregation seems to prevail over amyloid fibrillization since the beginning of incubation. 
The CD intensity continues to decrease from day 4 to 7 as a consequence of the formation 
of off-pathway aggregates and the increased number and size of scattering objects in 
solution
131
. No amyloid fibrils are formed during this period as indicated by the ThT 
fluorescence plateau in Figure 3.6B. 
Chapter 3: How to screen amyloid off-pathway modulators 
 
64 
 
 
Figure 3.6. Complementary data suggesting predominant off -pathway 
aggregates over amyloid fibrils. ( A) Symbols: depletion of soluble HEWL at pH 1.6 
and 60 ºC with time measured by UV absorption at 280 nm after filtration through a 
sterile 0.22 m filter. Lines: protein concentration dec rease predicted by the 
extended CLM. (B) Amyloid fibrillization followed by ThT fluorescence (black 
lines) under the same conditions of pH, temperature and initial HEWL concentration 
(1.76 mM) as in (A). Different colored lines: same numerical solution as in (a) 
expressed as the amyloid content increase  with time. HEWL depletion in (A) starts 
A 
B 
C 
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before, and continues after the fo rmation of amyloid fibrils in (B). (A,B) Numerical 
results obtained from Simulation 2 (Experiential Procedures) , using ka=1/7 h
1,
 
kb=10
-7
 and the range of kof f values indicated by the color bar in the right side; 
arrows: different instants of time where samples were analyzed using CD 
spectroscopy and DLS. (C) Far-UV CD spectra of HEWL samples incubated for 0, 1, 
2, 3, 4 and 7 days measured at 20 ºC and at a 1:400 dilution. Major changes in the 
CD spectrum occur during the first day of incubation and from day 4 to 7, when no 
measurable amount of new amyloid fibrils is formed.  
 
To gain insight into the size and morphology of the aggregates present in solution, 
samples incubated for different time periods were further analyzed using DLS and Atomic 
Force Microscopy (AFM)  Figure 3.7. The size distributions obtained from scattered light 
intensity measurements reveal how the populations of soluble protein and insoluble 
aggregates evolve with time (Fig. 3.7A). The relative weight of the peak centered near a 
hydrodynamic radius Rh of 2 nm is an indirect estimate of the amount of soluble HEWL. 
As shown in the inset of Figure 3.7A, the variation of this fraction during the incubation 
time resembles that of protein concentration measured by UV absorption in Figure 3.6A. 
This is another independent verification that phase transition processes occur before and 
after amyloid fibril formation. Even though particles with Rh greater than 50 nm are 
identified before incubation at 60 C, the first DLS dataset is not sufficiently resolved to 
distinguish between the different pre-aggregation species. As the incubation starts, the 
distribution of particles centered near 70 nm becomes better defined simultaneously with 
the formation of the amorphous aggregates. Coinciding with the period of fast ThT 
fluorescence increase (Fig. 3.6b), a third peak centered near ~500 nm emerges at the end of 
day 2 as the likely result of the formation of mature amyloid fibrils. After that, the two 
aggregate peaks become blended in a single distribution centered in a hydrodynamic radius 
still close to 100 nm but with the right tail exceeding the submicron range. Since the 
scattering intensity of a particle is proportional to the sixth power of its diameter, the 
results in Figure 3.7A suggest the existence of a population of amorphous aggregates with 
mean Rh of 70 nm dominating over a second population of greater Rh, presumably mature 
amyloid fibrils, having a widely dispersed size distribution owing in part to fibril breakage. 
Giventhe limitations of DLS to morphologically describe less prevalent, non-spherical 
particles
153
, the amyloidogenic samples were also characterized using AFM and 
Transmission Electron Microscopy (TEM). The selected AFM image in Figure 3.7B 
confirms that 1.76 mM HEWL solutions at pH 1.6 already contain amorphous aggregates 
before incubation at 60 ºC. Present in all analyzed samples, these precipitates generally 
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have the shape of a disk with height ~5 nm and diameter within the range 20-150 nm also 
obtained for Rh in Figure 3.7A. Figure 3.8 shows the results of further examinations using 
TEM, with small worm-like aggregates being identifiedin Figures3.8B and 3.8E. It remains 
unclear whether these protofibrils twist over themselves to form disk-shaped aggregates or 
continue to develop to form amyloid fibrils. In Figure 3.7C we surprisingly identified the 
presence of mature amyloid fibrils as long as 2 m and ~10 nm diameter at the end of the 
first day of incubation. Despite their size, these fibrils are scarce enough to remain 
undetected during ThT fluorescence and DLS measurements. Therefore, amyloid fibrils 
seem to grow much faster than they are nucleated in agreement with the low value 
estimated for parameter 
bk  (~10
7
). The AFM images in Figures 3.7D and 3.7E show well 
differentiated curvilinear fibrils, whereas the TEM images additionally report straighter 
fibrils generally surrounded by amorphous aggregates  see Figures 3.8E-F. These 
variations are the likely result of different sample handling, which in the case of AFM 
involved 1:400 dilution and spin-coated deposition onto silicon wafers. 
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Figure 3.7. Aggregation of 1.76 mM HEWL at pH 1.6 and 60 ºC followed by 
DLS and AFM. (A) Distribution of hydrodynamic radio  Rh obtained from DLS 
measurements at the different instants of time marked with an arrow in Figures 6 A 
and 6B. Inset: the relative weight of the soluble HEWL peak centered near 2 nm 
decreases with time. (B-E) Morphology of HEWL aggregates observed with AFM 
after (B) 0, (C) 1, (D) 3 and (e) 4 days incubation; color bar in the right side: height 
scale common to all AFM images.  
B C 
A 
D E 
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Figure 3.8. Aggregation of 1.76 mM HEWL at pH 1.6 and 60 ºC followed by 
Transmission Electron Microscopy. (A-C) Amorphous aggregates identified at the 
end of (A) 1, (B) 2 and (C) 3 days incubation; (D-F) amorphous aggregates and 
amyloid fibrils observed at the end of ( D) 2, (E) 3 and (F) 4 days incubation. Scale 
bars represent 200 nm. 
 
3.4 Discussion 
Similarly to other phase transition phenomena, amyloid fibril formation takes place 
via a nucleation and growth mechanism until thermodynamic equilibrium is reached. The 
amyloid pathway may however comprise parallel steps and intermediate species that are no 
less relevant for the development of amyloidosis and neurodegenerative diseases than the 
deposition of fibrils itself. Protein aggregation curves measured in vitro using amyloid-
specific dyes are shown to provide much more information about OPA than what is 
conventionally extracted. The set of canonical behaviors summarized in Figure 3.1 can be 
expected when off-pathway species are eitherabsent or present in minor amounts. Even if 
some of those kinetic results are not predicted by established theories, they are in 
conformity with the classical mechanism involving primary nucleation and auto-catalytic 
steps. The CLM was extended to include a third rate constant ( offk ) characterizing the 
parallel nucleation step. The numerical solutions of the three-parameter CLM unveil the 
kinetic signatures characteristic of OPA; these include non-linear variation of  1   
with time when plotted in a log-linear scale, highly variable endpoint signals, values of the 
50t  absolute scaling factor || below 1 and sublinear increase of 50v  with the protein 
A B C 
D E F 
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concentration. In cases of extensive OPA, increasing the protein concentration may even 
prolong the duration of the lag phase and decrease the amyloid aggregation rate. This angle 
of approach is, to our knowledge, totally original as the main focus has been on the 
detection and morphological/ toxicological characterization of the amorphous 
precipitates
121,123–125,129
. The new possibility of estimating the relative amounts of off-
pathway and amyloid aggregates accentuates the need for cataloguing the deleterious 
species in each disease. After deciding what aspect of protein aggregation one wants to 
target, extensive screenings of off-pathway modulators can from now on be routinely 
implemented. 
As a proof-of-concept the modified CLM was tested against ThT aggregation data 
of HEWL measured under conditions of low pH (1.6) and high temperature (60 ºC) known 
to produce off-pathway aggregates. The estimated values of 
ak , bk  and offk  suggest that 
off-pathway species are produced much earlier and at higher rates than amyloid fibrils, 
which, nevertheless, rapidly reach their mature size once the stable nucleus is formed. This 
was supported by complementary analysis ofsoluble protein depletion with time, far-UV 
CD spectra, particle size distributions measured using DLS and aggregates morphology 
observed using AFM and TEM. We further concluded that amorphous aggregates 
generally have the shape of a disk with diameters comprised between 20 and 150 nm, even 
though small worm-like aggregates were also identified. Amyloid fibrils with 10 nm 
diameter are consistently longerthan 1 m and show a broad size distribution as a likely 
consequence of fibril breakage. 
While offering an explanation for puzzling kinetic behaviors, our study contributes 
to a better understanding of the molecular basis of amyloid diseases and is expected to find 
practical application in neurodegenerative drug research. By using the analytical probes for 
OPA here proposed, libraries of small molecule compounds can be screened targeting the 
formation of amorphous aggregates without any additionalmeans being required besides 
the current amyloid-specific markers and high-throughput methods. Whether the kinetic 
signatures are attenuated or intensified by the screened molecules provides a valuable 
indication of their potential as off-pathway modulators. This therapeutic strategy aims at 
inhibiting or promoting OPA according to the disruptive or stabilizing effect that non-
fibrillar species may have on the regulatory mechanisms during disease. 
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Summary 
The screening of drugs candidates for the treatment of amyloidosis and 
neurodegenerative diseases frequently involves in vitro measurements of amyloid fibril 
formation. Macromolecular crowding and off-pathway aggregation (OPA) are, by different 
reasons, two important phenomena affecting the scalability of amyloid inhibitors and their 
successful application in vivo. On the one hand, the cellular milieu is crowded with 
macromolecules that drastically increase the effective (thermodynamic) concentration of 
the amyloidogenic protein. On the other, off-pathway aggregates, rather than amyloid 
fibrils, are increasingly appointed as the causative agents of toxicity. The present 
contribution reveals that insoluble off-pathway aggregates of hen egg-white lysozyme 
(HEWL) are a peculiar type of crowding agents that, unlike classical macromolecular 
crowders, decrease the thermodynamic concentration of protein. Illustrating this effect, 
OPA is shown to resume after lowering the fraction of insoluble aggregates at constant 
soluble HEWL concentration. Protein depletion and thioflavin-T fluorescence progress 
curves indicate that OPA rebirth is not accompanied by additional amyloid fibril 
formation. The crystallization-like model extended to account for OPA and time-dependent 
activity coefficients is able to fit multiple kinetic results using a single set of three 
parameters describing amyloid nucleation, autocatalytic growth and off-pathway 
nucleation. The list of fitted results notably includes the cases of aggregation rebirth and all 
types of progress curves measured for different HEWL concentrations. The quantitative 
challenges posed by macromolecular crowding and OPA find here a unified response with 
broader implications for the efficient design of on- and off-pathway inhibitors. 
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4.1 Introduction 
Macromolecular crowding and off-pathway aggregation (OPA) are two subjects 
under intense, yet mostly unlinked, research attention. Both phenomena play an important 
role on the pathogenesis of amyloidosis and neurodegenerative diseases characterized by 
the accumulation of amyloid deposits in organs and tissues. Fluid media crowded with 
macromolecules promote the formation of amyloid fibrils owing to volume-excluding 
effects consisting of steric interactions that may affect the native protein 
conformation
154,155
, increase the effective protein concentration
151,156
 and interfere with the 
diffusive behavior of macromolecules
157
. In depth analysis of these effects involves adding 
high concentrations of inert macromolecules to in vitro systems in order to reproduce the 
crowded environment of most biological fluids, whether intracellular or extracellular
154,158
. 
The discovery in 2012 that the crowding agent Ficoll-70 and its monomer, sucrose had 
approximately the same protein stabilizing effect contributed to extend the range of 
excluded volume effects to include non-specific soft interactions
159,160
. Off-pathway 
aggregates are hereby investigated as crowding agents during hen egg-white lysozyme 
(HEWL) aggregation. This aspect of OPA remains, to our knowledge, totally unexplored 
as the main focus has been on the detection and morphological/toxicological 
characterization of the non-amyloidogenic species
121,129,161,162
. By 'off-pathway aggregates' 
we are considering insoluble, high-order oligomers and precipitates
163–165
, and we are 
excluding soluble oligomers and insoluble protofibrils whose intermediate role in amyloid 
assembly is not totally defined
166–168
. 
The association between the two seemingly unconnected subjects stems from our 
effort to quantitatively characterize OPA from amyloid fibrillization kinetics
169
. We 
realized that off-pathway aggregates not only deplete the soluble amyloid pool via an 
additional kinetic step, as they decrease the effective protein concentration by means of 
thermodynamic effects that needed characterization. A similar objective has previously 
been faced while modeling macromolecular crowders as modifiers of the activity 
coefficient value   relating the overall density of molecules (or apparent concentration) C  
with the thermodynamic activity or effective concentration a ( )C
169,170
. Existing 
statistical mechanical theories use necessarily simple descriptions of crowding agents as 
hard-spheres or hard-rods in a practical alternative to computational simulation methods of 
molecular dynamics
171
. Experimental validation of these theories often relies on indirect 
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measurements of amyloid fibrillization kinetics in the presence of model crowders, such as 
Dextran or Ficoll
170,171
. In dealing with activity coefficients, we suggested that protein 
concentrations measured after long incubation times ( C ) are a closer indicator of the 
thermodynamic equilibrium that takes place when the chemical potential of the solution 
equals that of the insoluble fraction
13
. In absence of OPA, C  is equivalent to the amyloid 
apparent solubility *
aC , which in turn, should correspond to the amyloid activity 
*a  under 
very dilute, ideal solutions. Enthalpic disturbances involving, e.g., macromolecular 
crowders, off-pathway aggregates or hydrophobic interfaces do not alter the intrinsic value 
of *a  but are likely to change the apparent solubility *
aC  and, consequently, the value of 
the activity coefficient under saturated conditions *.a  In the presence of OPA, the steady-
state concentration C  may as well differ from 
*
aC  in the cases where off-pathway 
aggregates are less soluble than amyloid fibrils, for which C  corresponds to the off-
pathway solubility 
*
offC
126
. Therefore, besides competing kinetically with amyloid fibrils 
for soluble protein
13
, off-pathway aggregates may have an additional thermodynamic role 
either disrupting or stabilizing the regulatory mechanisms during disease
126
. 
Different solubility values reflect the structural stability of the different aggregation 
states and determine, in part, their relative abundance in the cell
172
. Another important part 
is determined by kinetic barriers for nucleation and growth
1
, whose relative magnitudes 
were recently determined for HEWL aggregation with identification of the main signatures 
left by the presence of OPA; namely, amyloid conversion   expressed as  1   and 
represented as a function of time in semi-log plots becomes highly non-linear, whereas the 
half-life coordinates of time and aggregation rate become weakly dependent on the initial 
protein concentration 
0C
6
. While important for the development of a new class of off-
pathway regulators, this analysis needed further thermodynamic insights in view of the 
holistic quantitative representation of amyloid aggregation. The present contribution 
provides an important piece of this puzzle thus helping to close the gap between in vitro 
results and their physiological counterparts during drug discovery.  
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4.2 Experimental Procedures 
Protein Preparation: 
HEWL powder obtained from Merk KGaA (Darmstadt, Germany) was dissolved in 
25 mM HCl pH 1.6 and dialyzed against 25 mM HCl, pH 1.6, using a cut-off 3500 Da 
membrane (Spectrum, Fisher Scientific). The concentration of the dialyzed protein solution 
was determined by absorbance measurements at 280 nm using an extinction coefficient of 
37752 M
1
cm
1
. Protein stocks were stored at 4 ºC for no longer than one week. 
Protein Depletion Experiments: 
The concentration of soluble HEWL was followed spectrophotometrically over 
time under amyloidogenic conditions reproducing the Thioflavin-T (ThT) fluorescence 
experiments previously carried out by us
167
. Five series of independent 1.0ml samples of 
HEWL with final concentrations of 0.60, 0.93, 1.25, 1.39 and 1.76 mM were incubated at 
60ºC. For each concentration series, one sample at a time was periodically taken from the 
incubator and the suspension was filtered through a sterile 0.22 μm pore size PES 
membrane filter (Jet Biofil). After 1 hour at room temperature, the filtrate was diluted 1:50 
in 25 mM HCl pH 1.6 and analyzed at 280 nm using 1 cm pathlength quartz cuvettes 
(Hellma GmbH & Co. KG, Müllheim, Germany) and an extinction coefficient of 37752 
M
1
cm
1
. 
Protein Depletion with Expanded Mixture Volume: 
The effect of the fraction of aggregates on the rate and extension of protein 
depletion was investigated by expanding the reaction volume at constant soluble HEWL 
concentration, temperature and pH. The mixture volume of some of the samples used in 
protein depletion experiments was expanded from 1.0 ml to 2.0 ml after elapsed a variable 
period time (of 240, 456, 456, 360 and 456 h for the 0.60, 0.93, 1.25, 1.39 and 1.76 mM 
samples, respectively). Thermostatized HEWL solutions freshly prepared to the same 
soluble protein concentration as that of the incubated samples (0.52, 0.67, 0.70, 0.91 and 
0.96 mM for the 0.60, 0.93, 1.25, 1.39 and 1.76 mM samples, respectively) were used. 
Samples with and without mixture volume expansion continued incubation and were 
subject to periodic soluble HEWL concentration measurements as described for protein 
depletion experiments. 
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Dynamic Ligth Scattering (DLS): 
DLS measurements were performed using an ALV/DLS/ SLS-5000F, SP-86 
goniometer system (ALV-GmbH, Langen, Germany) as previously described
167
. The 
previous analysis of six independent 1.76 mM HEWL samples incubated for different 
periods of time at 60 ºC and pH 1.6
167
 was complemented with new measurements using 
freshly prepared 3.57 mM HEWL samples in 0.2 M sodium acetate buffer, pH 4.7. 
Measurements were made at least three times at a scattering angle 90º to the incident beam 
for 5-10 min. 
Activity coefficients: 
The results obtained during protein depletion experiments with and without mixture 
volume expansion showed that the apparent HEWL concentration estimated for long 
incubation times C  is a function of the fractional volume of aggregates, with lower values 
of  obtained for lower insoluble aggregates content. The different values of C  should, 
however, correspond to the same thermodynamic activity *a  of the less soluble, off-
pathway aggregates. This activity was approximated to the limit  value of 0.40 mM 
obtained for the less concentrated HEWL samples after the volume expansion step since 
these are the conditions originating the lowest fraction of insoluble aggregates in solution. 
The activity coefficients under saturated conditions 
*
off  were estimated dividing the fixed 
value of  by the limit  values obtained for each protein depletion experiment carried 
out without mixture volume expansion.  
Mathematical Model Derivation: 
In its simplest version, the crystallization-like model (CLM) has a closed-form 
solution describing how the molecular mechanisms of nucleation and growth affect the 
evolution of amyloid conversion (  ) with time ( t ) during seeded or unseeded 
reactions
6,130
. The 2-parameter CLM equation includes the autocatalytic rate constant 
ak  
accounting for the fibril elongation and secondary nucleation phenomena
6,167
, and the rate 
constant 
bk indicative of the relative magnitude of primary nucleation over autocatalytic 
steps. We have recently extended the CLM to include OPA by introducing a parallel 
nucleation step with normalized rate constant 
offk
167
. Similarly to amyloid homogeneous 
nucleation, this step is considered to be second-order in relation to the thermodynamic 
C
C
*a C
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driving force for phase transition represented by supersaturation S . As time-dependent 
values of the activity coefficient   are not easily obtainable, the primary definitions of 
aS
and 
offS : 
 
* *
* *
i i
i
i i
C C
S
C
 


  (4.1) 
have been approximated by the a relative concentration differences defined as 
 
*
*
i
i
i
C C
C


  (4.2) 
for either amyloid aggregation (subscript )i a  or OPA (subscript )i off . As a 
consequence of this approximation, rate constants fitted to kinetic data are only apparent 
estimators of the real event frequency of nucleation and growth. The differential form of 
the 3-parameter model equations reads: 
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    
 
 (4.3b) 
where
a  corresponds to the instantaneous amount of amyloid fibrils ( am ) over the 
total amount expected in the absence of OPA (
aM ); m  is the instantaneous amount of total 
aggregates; 
*
offk  is the absolute rate constant for OPA; and V  is the mixture volume. The 
definition of 
a a am M   implies that final value of 1 is only reached when no off-
pathway aggregates are formed. In all other occasions, the value of 
a  measured for long 
incubation times (
,a  ) represents the amount of amyloid fibrils really produced over the 
maximum amount expected in the absence of OPA. Therefore, the conventional amyloid 
conversion  , computed, e.g., from the ThT fluorescence signal and comprised between 0 
and 1, is equivalent to 
, .a a     If the instantaneous concentration of soluble protein 
C  is known, the instantaneous conversion in total aggregates directly follows from mass 
balance to obtain: 
 0
0 0
C Cm
M C C



 

 (4.4) 
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with
0M  being the final amount of total aggregates. The concentration of protein for 
long reaction times  corresponds to the apparent solubility of the less soluble species, 
which, in the case of HEWL, are the off-pathway aggregates (i.e., 
* )offC C 
167
. Equally, if 
the instant of amyloid saturation is known (using, e.g., amyloid-specific dyes), then the 
apparent amyloid solubility *
aC  corresponds to the value of C  at that instant. The 0aM M  
ratio is then computed as: 
 
*
0
0 0
a aM C C
M C C



 (4.5) 
In the present development of the CLM, activity-based supersaturation levels S  are 
used in the model equations to replace the less realistic   values. This involves using Eqs. 
4.4 and 4.5 to express Eq. 4.1 as a function of the integration variable   for the cases of 
(i) amyloid aggregation, 
 0
* *
,0 ,0
1
1 1a
a a a a a
S M
M
 

   
   
      
   
 (4.6a) 
and (ii) OPA, 
  * *
,0 ,0
1
1 1
off
off off off off
S  

   
 
     
 
 (4.6b) 
Accordingly, Eqs. 4.3a and 4.3b can now be expressed in terms of activity-based 
supersaturation levels S , conversion   and dimensionless time 
ak t  , 
 
,0 ,0
d
d
a a a
b a
a a
S S
k


  
 
   
 
 (4.7a) 
 
2
,0 0 ,0 ,0
offa a a
b a off
a a off
SS M Sd
k k
d M


   
  
        
   
 (4.7b) 
using the 
,0a aS   and ,0off offS   definitions given by Eqs.4.6a and 4.6b, 
respectively, and the definition of
0aM M  given by Eq. 4.5; the definition of offk  follows 
from the direct dependence of 
ak  on ,0a ,0( )a ak 
6
 and from the alternative definition 
of the total amount of aggregates as  0 0 wM C C M V  : 
C
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* 2 *
,0 ,0
0 ,0
off off off off
off
a w a
k V k
k
k M M
 
 
 
    
 
 (4.8) 
where
wM  is the molecular weight of the amyloidogenic protein.  
Numerical Methods: 
Equations 4.7a and 4.7b were numerically solved using Matlab subject to the 
initial conditions  0 0a   and  0 0   and testing the set of rate constants ak , bk , offk  
that best described the  t  and  t  progress curves measured during ThT fluorescence 
and protein depletion experiments, respectively. Other unknowns besides the fitting 
parameters include values of 
0  and 0aM M  that can be computed from Eqs. 4.2 and 4.5 
using the different initial HEWL concentrations 
0C , and the values of 
*
aC  and C  obtained 
from the protein depletion experiments. Amyloid fibrils are not considered to dissolve once 
the thermodynamic concentration of soluble protein decreases below amyloid solubility. 
After that limit, amyloid supersaturation 
aS  is considered 0. The time-dependent activity 
coefficients were estimated as described above using the linear relationship between   and 
the concentration of insoluble aggregates (Table 4.1 and inset of Figure 4.1). Numerical 
fitting was initially carried out adopting 
ak -normalized units of time ( )  thus reducing the 
fitted parameters to the values of 
bk and offk , which determine the amyloid and off-pathway 
timescales. After the relative timescales matched the observed ones, 
ak  was directly 
calculated as the t  ratio using the values of   (simulated) and t  (measured) that 
corresponded to the same total conversions  . The theoretical results were represented by 
the normalized amyloid conversion profiles     , ,a at t     and by the concentration 
depletion profiles  C t  computed from  t  using Eq.4.4. In a supplementary validation 
test, the fitted model was used to simulate the mixture volume expansion experiments 
carried out at constant HEWL concentration, temperature and pH; for that, Eqs.4.7a and 
4.7b were solved subject to modified initial conditions corresponding to the amyloid 
conversion, total conversion and soluble HEWL concentration ( a ,   and C , 
respectively) predicted by the numerical simulations for the instants at which the mixture 
volumes were expanded. From that point on, the concentration of total aggregates used to 
calculate the activity coefficients were multiplied by a factor of 1 2  (to account for the 
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dilution of the insoluble phase), and the new values of 
0C  and C  were used to compute 
0aM M and ,0off .  
4.3 Results 
'Solvation-in' effects: 
Our practical approach to quantify OPA-induced thermodynamic effects is based on 
the concept of thermodynamic solubility as the activity of the solution phase equilibrating 
that of the solid phase
82
. If present during HEWL aggregation, enthalpic effects are 
expected to influence the equilibrium concentration of soluble protein estimated for long 
incubation times C  but not the intrinsic thermodynamic activity 
*a  of the protein 
molecules at the aggregate-solution interface
6,167
. Table 4.1 shows that higher values of C  
are obtained as the initial HEWL concentration increases indicating that the final 
concentrations correspond to apparent solubility values. Consequently, the final amount of 
insoluble aggregates expressed as 
0( )C C  did not increase with 0C  as much as it would 
be expected in the case of constant C . As more insoluble aggregates are present, higher 
concentrations of HEWL molecules appear to be needed in order to achieve the same 
thermodynamic activity at the end of the assay. Therefore, and contrarily to the classical 
macromolecular crowders, HEWL aggregates decrease the effective protein concentration 
in solution. While promoting protein solubilization, this effect is associated to an increase 
in the solvent accessible surface of HEWL molecules
93
. The type of interactions here 
involved is certainly not limited to the van der Waals forces and repulsive electrical 
double-layer forces of the classical electrostatic theories, but should belong to the myriad 
of dispersion forces thought affect biological colloid systems
173
. This is especially so for 
the highly non-ideal amyloidogenic environment where hydration forces and quantum 
forces are interplaying in a ion-specific manner
173
. We borrow the concepts of salting-in 
and salting-out used to describe the action of salts
93
 to generically name as 'solvation-in' 
and 'solvation-out' effects the increased/decreased protein solubility caused by the presence 
of protein aggregates and other colloids in solution. 
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Table 4.1. Protein depletion experiments carried out for different initial HEWL 
concentrations 
0C  provide estimations of the saturation HEWL concentration C , 
final amount of total aggregates 
0( )C C  and apparent amyloid solubility 
*
aC . The 
value of C  is the apparent off-pathway solubility from which the activity 
coefficient 
*
off  is estimated in relation to a reference solubility value (0.40 mM) 
estimated for low aggregate content. 
0C  (mM) C  (mM) 0( )C C  (mM) 
*
aC  (mM) 
*
off  (-) 
0.60 0.45 0.15 0.50 0.89 
0.93 0.45 0.48 0.71 0.89 
1.25 0.50 0.75 0.92 0.80 
1.39 0.55 0.79 1.10 0.67 
1.76 0.70 1.06 1.30 0.57 
 
Changing the focus from total aggregates to amyloid fibrils, we look now to the 
stages of aggregation coinciding with the final plateau of ThT fluorescence experiments
167
. 
The fibril-solution equilibrium required incubation periods no longer than 90 h, after which 
the apparent amyloid solubility values *
aC  could be estimated (Table 4.1). The existence of 
solvation-in effects is again suggested by increasing *
aC  values as the initial HEWL 
concentration increases. This variation partially explains the weak 0C  dependence of the 
end-point ThT fluorescence F  described in Figure 4.1A: in principle, F  should increase 
linearly with 0C  as the total amount of amyloid fibrils is determined by the 
*
0( )aC C  
difference (red line). Since in practice *
aC  also increases with 0C , the expected end-point 
fluorescence signal becomes a weaker function of the initial HEWL concentration (blue 
line). Despite the improvement, the new dependency is not sufficient to reproduce the 
nearly invariant F  values obtained for HEWL concentrations comprised between 
0.60mM and 1.76 mM (symbols). As demonstrated next, the kinetic effect produced by 
OPA not only provides the other part of the explanation as it rationalizes the high 
variability associated to the end-point signal (error bars). This is to be illustrated within the 
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CLM framework taking into account self-crowding effects in the definition of the 
thermodynamic driving force for aggregation. As the phase transition evolves towards 
increasing amounts of total aggregates, activity coefficient values (  ) progressively 
smaller than 1 are utilized in Eq.4.1 in accordance with the linear relationship obtained 
under saturation conditions (Figure 4.1A, inset).  
 
Figure 4.1. The effective concentration of soluble HEWL is influenced by the 
amount of insoluble HEWL aggregates in solution. (A) Open symbols and error bars: 
mean values and standard deviations of the end -point ThT fluorescence F∞  measured 
for different initial HEWL concentrations C0  at pH 1.6 and 60  ºC. Dots connected by 
red line: in the absence of solvation-in effects the end-point signal is expected to 
linearly increase with C0  as the amount of amyloid fibrils is given by the  (C0- Ca*) 
difference and the amyloid solub ility Ca*  is constant. Dots connected by blue line: 
since Ca*  increases with C0  (Table 4.1) the theoretical F∞  (C0) dependency becomes 
attenuated. This variation alone is not sufficient to match the measured trend. Inset: 
solvation-in effects illustrated by decreasing activity coefficients o f f* as the amount 
of total aggregates (C0- C∞) increases (symbols).  The solid line is a linear fit to the 
data with slope 0.35 mM1 and the y-intercept set to 1.  (B) Distribution of 
hydrodynamic radii R h obtained from DLS measurements after different periods of 
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incubation (color bar).  Solid lines: incubation of 1.76 mM HEWL samples at pH 1.6 
and 60 ºC
1 67
. Dashed line: freshly prepared 3.57 mM HEWL samples at pH 4.7. The 
first aggregates are formed upon acidification with a size distribution centered near 
70 nm that is in good agreement with previous morphological analysis of the 
insoluble HEWL precipitates using advanced microscopy technique
1 67
.  
 
The DLS measurements in Figure 4.1B indicate that the first HEWL aggregates are formed 
upon acidification with a size distribution centered near 70 nm. This approximate size falls 
within the range of 20-150 nm observed for HEWL precipitates using Atomic Force 
Microscopy and Transmission Electron Microscopy
167
. The combination of these 
observations with the protein depletion data shown below (Figure 4.2) indicate that the 
formation of insoluble off-pathway aggregates starts immediately after incubation at pH 
1.6 and 60 ºC, and dominates thereafter over any other process of aggregation. 
Kinetic and thermodynamic effects caused by OPA: 
To validate our description of amyloid fibril formation in the presence of OPA, the 
extended CLM was tested against HEWL aggregation progress curves measured by two 
distinct, yet complementary, spectroscopic methods: UV absorption and ThT fluorescence. 
The obtained results are represented in Figure 2, with each panel corresponding to different 
initial HEWL concentrations. 
 
Figure 4.2. The CLM extended to consider OPA and solvation effects is able 
to predict protein depletion and amyloid fibrillization curves measured for different 
HEWL concentrations. Symbols: variation with time of the soluble HEWL 
concentration measured at pH 1.6 and 60 ºC for (A) C0=0.60 mM, (B) 0.93 mM, (C) 
1.25 mM, (D) 1.39 mM and (E) 1.76 mM HEWL. Colored lines: predictions of the 
CLM for corresponding values of C0 using ka =0.24 h
1
,  kb =1.010
7
 and the values 
of kof f indicated by the color bar. Insets: normalized ThT fluorescenc e increase 
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measured (black lines) and simulated (different colored lines) under the same 
conditions as the C(t) curves. The variability of the ThT fluorescence progress 
curves can be described by changeable values of the nucleation rate constants kof f  
(color bar) and kb (not shown).  
 
It is remarkable that a single set of ak , bk , offk  fitted parameters is able to describe 
each pair of independent results in Figure 4.2, given that protein depletion (main graphs) 
and amyloid fibrillization (inset graphs) not only require different techniques to be 
followed as they take place over very distinct time scales. As documented by the ( )t  
progress curves, amyloid fibrils are principally formed within the period of 3090 hours, 
whereas HEWL depletion generally starts before and continues long after this interval of 
time. Because amyloid fibrillization accelerates protein clearance from solution (see the 
initial inflections in the theoretical ( )C t  curves) the two types of progress curves cannot be 
dissociated from each other. It is no less relevant that our simulation is able to capture the 
effect of changing HEWL concentration (Figure 4.2A to Figure 4.2E) considering the 
intricate role that 0C  has on the end-point fluorescence, duration of the lag phases and 
limit aggregation rates. On account of the stochastic nature of nucleation steps, the 
corresponding amyloid ( bk ) and off-pathway ( offk ) rate constants are adequately described 
by intervals of values as an alternative to single fits. By admitting the range of 
offk  values 
given in the color bar of Figure 4.2, the observed variability of experimental results can be 
particularly well described for higher HEWL concentrations (Figures 4.2D and 4.2E). 
Under these conditions, amyloid fibrils are a smaller fraction of the total aggregates and, 
therefore, OPA plays a more important role. The high variability of amyloid progress 
curves observed in the insets of Figures 4.2A to 4.2C can also be replicated by assuming an 
interval of bk  values around the fitted value (data not shown). The margin of error 
admissible for the CLM parameters is large enough to incorporate the influence of 
,0a  and 
,0off  on the concentration-independent rate constants ,0a ak  , ,0b ak   and ,0 ,0off a offk   . 
According to the data in Table 1, 
,0a  is comprised between 0.20 and 0.36 whereas 
,0 ,0a off   is comprised between 0.17 and 0.59. 
The fitting results are used in Figure 4.3 to describe the influence of the initial 
HEWL concentration on amyloid fibril formation. Amyloid conversion is expressed in 
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Figure 4.3A as the amount of fibrils effectively produced over the maximum amount 
expected in the absence of OPA (
a ).  
 
Figure 4.3. The presence of OPA and crowding-in effects attenuate the C0-
dependency of amyloid kinetic coordinates.  (A) Fractional amyloid signal ( αa)  
represented as a function of the dimensionless time ( kat) as predicted by the 
extended CLM using the same nucleatio n rate constants kb and kof f as in Figure 2 and 
the values of C0 indicated in each graph. (B) Open symbols and error bars: same 
experimental data as in Figure 4.1. Different colored dots connected by lines: 
predicted end-point amyloid signals (F∞) obtained from the product of the maximum 
fluorescence values expected in the absence of OPA (blue dots) and the limit values 
of αa calculated for long reaction times (αa ,∞) using the values of kof f indicated by 
the color bar. (C) Simulation data represen ted in terms of the normalized amyloid 
signal (α=αa/αa ,∞) for C0=0.60 mM (blue), 0.93 mM (light blue),  1.25 mM (green), 
1.39 mM (orange) and 1.76 mM (red) after choosing a fixed value of kof f (7.510
3
). 
Arrows indicate increasing C0 values. Changing the value of C0 had no major effect 
on the duration of the lag phases or on the limit aggregation rates. Inset: 
Experimental data obtained during HEWL aggregation showing the variation of the 
endpoint ThT fluorescence emissions with the time required to reach 50  % 
completion ( t5 0) - same color code as in the rest of the panel.  
 
The successive graphs in Figure 4.3A show that increasing protein concentrations 
favors the formation of off-pathway aggregates over amyloid fibrils. This kinetic 
promotion of OPA concurs with the thermodynamic solvation-in effect to complete the 
explanation of the weak variation of the end-point fluorescence with 
0C  that was 
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previously identified in Figure 4.1A. The simulated end-point signals obtained in Figure 
4.3A are shown in Figure 4.3B to reproduce very well the measured trend. Although a 
counterintuitive possibility, negative scaling laws are also admitted to occur when OPA is 
more prevalent - higher 
offk  values in Figure 4.3B. Additionally, the summary of fitted 
curves presented in Figure 4.3C suggests non-trivial behaviors of the half-life coordinates, 
with higher HEWL concentrations not necessarily meaning shorter aggregation times 
50t  or 
faster aggregation rates 
50v . Formerly appointed as OPA signatures
167
, the peculiar 
variations of 
50t  and 50v  with 0C  are here shown to justify the simultaneous occurrence of 
solvation-in effects in order to explain the whole experimental data in a quantitative 
manner. The inset in Figure 4.3C addresses the variability of F  as the result of the 
competition between amyloid and off-pathway formation
13,166,167
. As some of the soluble 
protein also produces ThT-negative precipitates, the stochastic properties of nucleation 
steps are propagated into poorly reproducible F  values. Faster amyloid nucleation rates 
(i.e. higher 
bk  values) are expected to simultaneously provoke more intense end-point 
signals and shorter induction times. Only partially perceptible in the inset of Figure 4.3C, 
this inverse proportion is likely affected by changeable off-pathway nucleation rates that 
scatter the measured F  values to a greater extent.  
Supplementary validation experiments: 
An immediate consequence arising from the extended CLM is that protein 
aggregation can be reactivated by decreasing the fraction of insoluble aggregates in 
solution. This hypothesis was tested during protein depletion experiments involving 
mixture volume expansion, which, as described in Material and Methods and graphically 
illustrated in Figure 4.4A, was carried out without changing the HEWL concentration, 
temperature or pH. We expected and confirmed that lower fractions of insoluble 
aggregates would reduce the solvation effects and promote additional HEWL aggregation. 
Although unaffected at the instant of the perturbation, the subsequent decrease of the molar 
HEWL concentration confirms that protein aggregation was boosted (Figures 4.4B to 
4.4F). Similar tests involving ThT fluorescence monitoring evidenced no amyloid signal 
increase after the mixture volume expansion (data not shown) indicating that only OPA 
was promoted. As the experiments carried out for higher protein concentrations also 
produced more insoluble aggregates, the addition of clear HEWL solutions had, in those 
cases, more pronounced aggregation promoting effects (compare Figures 4.4B to 4.4F). 
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This is explained as the result of larger gains in the thermodynamic activity of HEWL 
when higher fractions of insoluble aggregates are diluted to one half; in the limit case of 
clear incubating solutions (without aggregates) no variation on the effective HEWL 
concentration would be induced and the aggregation propensity would remain unchanged. 
The same CLM parameters previously demonstrated to describe multiple kinetic results in 
Figures 4.2 and 4.3B are now shown to effectively predict the new HEWL depletion data 
represented in Figures 4.4B to 4.4F. Notice that the successful fittings would not be 
possible without extending the off-pathway-CLM to include activity coefficients seeing 
that the aggregation boost is caused by deliberately changing the magnitude of the 
salvation-in effects.  
 
Figure 4.4. Protein aggregation is reactivated after decreasing t he fraction of 
insoluble aggregates in solution. (A) Schematic variation the aggregation propensity 
(Wifi symbol) and soluble HEWL concentration (lines) with (blue) and without (red) 
expansion of the mixture volume. Plastic microtubes represent independent  samples 
taken for analysis after different periods of incubation. At a fixed time instant, a 
number of samples were subject to volume expansion by the addition of 1.0  ml of 
clear protein solution prepared to the same HEWL concentration of the incubated 
mixture. (B-F) Lines: Protein depletion curves simulated using the same set of CLM 
parameters as in Figure 4.2 for the experiments started with (B) C0=0.60 mM, (C) 
0.93 mM, (D) 1.25 mM, (E) 1.39 mM and (F) 1.76 mM HEWL; same color code as in 
(A). A selection of fixed kof f  values of (B) 12.510
3
, (C) 10.0103,  (D) 12.5103,  
(E) 7.5103 and (F) 7.5103 was made from the color bar list in Figure 4.2. Filled 
circles: same experimental data as in Figure 4.2A to 4.2E, respectively. Open 
circles: variation of soluble HEWL concentration measured after the reaction volume 
expansion.  
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4.4 Discussion 
We have shown that a set of three model parameters is enough to quantitatively 
explain multiple and surprising amyloid aggregation results in the presence of off-pathway 
crowding agents. The theoretical framework provided by CLM is confirmed using a 
repertoire of kinetic data measured during ThT fluorescence and protein depletion 
experiments of HEWL at low pH (1.6) and high temperature (60 C). By explaining the 
amyloid and OPA progress curves measured at different HEWL concentrations, the new 
model is also quantitatively describing puzzling scaling laws of half-life coordinates (both 
50t  and 50v ) and end-point amyloid signal ( F ) with 0C . Despite their singularity, similar 
behaviors have been identified by other authors and in other systems than 
lysozyme
142,144,166,174
. By successfully characterizing the changes on the relative 
importance of amyloid and off-pathway aggregation as different conditions are tested, the 
unexpected high variability of F  is also understood as the result of stochastic variations 
on the nucleation rates; poorly reproducible protein aggregation is a recurring problem 
while studying different amyloidogenic proteins
108,145,175,176
. Given the different and 
independent experimental data analyzed, the number of degrees of freedom was reduced to 
a point where the CLM was actually used to predict (rather than to fit) the outcome of new 
experiments involving mixture volume expansion. These experiments confirmed that 
protein aggregation can be reactivated by decreasing the fraction of insoluble aggregates in 
solution. Crucial for the overall quality of the validation tests, the solvation-in effect 
introduces a thermodynamic dimension to the role of off-pathway aggregates during 
amyloid fibrillization. The common practice in past and recent literature of assuming the 
monomer concentration alone as the driving force for phase transition gave rise to a series 
of known inconsistencies between theoretical predictions and measured kinetic data
34,167
. 
By expressing the nucleation and growth steps as a function of supersaturation, the CLM is 
exempted from those limitations and is able to accommodate the effect of crowding agents 
on protein solubility. Figure 4.5A schematically presents a description of indirect solvation 
effects as responsible for altering the tendency of soluble protein to form aggregates 
according to the availability of water molecules in solution. Using as reference the 
enthalpic solvation equilibrium (top), the introduction of amyloid fibrils and off-pathway 
aggregates (right side) is a disturbance to this balance by recruiting protein molecules to 
the solid-liquid interface. As a result, the initially saturated polypeptide (intermediate color 
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shade) becomes undersaturated in solution (lighter color shade) while the surface-adsorbed 
macromolecules remain under phase equilibrium. Should the departing point consist of a 
supersaturated solution, the addition of aggregates would seed the formation and growth of 
more amyloid fibrils given that surface adsorption is a precursor step of integration. 
Macromolecular crowding, on the contrary, is known to upshift the effective concentration 
of the amyloidogenic protein and promote aggregation
151,169
. From the analogy with the 
salting-out effects provoked by electrolytes
177,178
, the availability of water molecules is 
represented to decrease in the presence of macromolecular crowders (left side of Figure 
4.5A). The formation of the hydration shell around the added molecules is responsible for 
the increased thermodynamic activity of the soluble protein (darker color shade). This 
'solvation-out' mechanism is independent on whether the external agent is a polymer or its 
monomeric equivalent
159
.  
 
Figure 4.5. Indirect solvation effects during amyloid fibril formation. (A) 
Graphic illustration of solvation-out and solvation-in effects provoked by 
macromolecular crowding agents and protein aggregates, respectively. The 
propensity of protein molecules to aggregate is higher when the availabil ity of water 
decreases (solvation-out) and vice-versa (solvation-in). (B) Illustrative protein 
depletion curves in the absence of OPA (green line), in the presence of OPA without 
solvation-in effects (blue line) and in the presence of OPA with solvation-in effects 
(red line).  Inset: Corresponding variation of the amyloid signal with time. Shaded 
areas comprise an equal period of time (t1).  
 
Although the simplified scheme does not include conformational and volume 
excluding effects resulting from molecular confinement, it provides a conciliatory view of 
macromolecular crowding not exclusively dependent on hard-sphere, entropic 
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interactions
159,179–181
. From the parallel with the present work, we speculate that 
macromolecular crowding can equally be characterized (i) using effective supersaturation 
levels as the driving force for protein aggregation, and (ii) measuring the soluble protein 
concentrations after long incubation times to estimate thermodynamic activity coefficients. 
The kinetic outcomes expected in those cases do not necessarily oppose the general 
tendency summarized in Figure 4.5B for off-pathway aggregates, which, differently from 
macromolecular crowders, are not considered to induce volume excluding effects. Added 
to this, OPA is kinetically competing with amyloid fibrillization for soluble protein, 
whereas classic crowding agents are generally inert molecules. The competition between 
amorphous and amyloid aggregation events explains part of the differences between green 
(without OPA) and blue (with OPA) progress curves represented in Figure 4.5B, namely 
the earlier concentration drop in the presence of OPA and the lower end-point signal 
shown in the inset. The protein depletion curve in blue also represents an increased 
reaction extent caused by the formation of off-pathway aggregates which, at least for 
HEWL, are less soluble than amyloid fibrils. The existence of solvation-in effects does not 
change the interfacial activity of the insoluble phase (not represented in Figure 4.5B) but 
increases the apparent concentration of protein under equilibrium conditions (red progress 
curve in Figure 4.5B). As a result, although lower amounts of total aggregates are 
produced in the presence of solvation-in effects, the final thermodynamic availability of 
protein molecules remains unaltered in the two OPA cases shown in the graph. Besides 
affecting the magnitude and variability of the end-point amyloid signal, OPA interferes 
with the fibrillization kinetics in a complex manner that is not totally evident in the inset of 
Figure 4.5B. At the same time that the rates of amyloid nucleation and growth are slowed, 
the rate of protein depletion is increased (due to the extra phase transition step) - while the 
former outcome delays the onset of the final plateau phase, the latter anticipates its arrival. 
Solvation-in effects are, in turn, responsible for faster decrease of the supersaturation levels 
leading to faster overall amyloid kinetics but lower amounts of fibrillar aggregates. As the 
previous analysis of Figure 4.3 demonstrated, both OPA and solvation-in effects contribute 
for weakening the influence of the initial protein concentration on typical kinetic 
coordinates such as the duration of the lag-phase, limit aggregation rate and end-point 
amyloid signal.  
In addition to the experimental observables here summarized, non-linear  1   
vs. time log-linear plots complete the list of signatures associated to OPA. We believe that 
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a new class of off-pathway regulators can hereafter be screened based on their ability to 
amplify/attenuate these kinetic indicators
167
. The finding that off-pathway species 
additionally deplete soluble protein through solvation-in mechanisms is expected to have a 
twofold importance for the development of new drugs targeting protein aggregation: the 
total aggregates content emerges as an important variable affecting the scalability of in-
vitro results, and OPA might promote (unpleasantly) surprising losses of physiological 
function. First, the recurrent principle that crowded environments promote aggregation 
may not apply when the crowding agent consists of proteinaceous aggregates. It remains to 
be ascertained how differently packed milieus interfere with the efficacy of drug 
candidates. Second, therapeutic strategies deflecting the aggregation pathway to non-
amyloidogenic precipitates might also promote loss-of-function cascades involving more 
extensive aggregation, lower amounts of soluble protein, and protein inactivation. On the 
other hand, OPA may arguably represent a competing pathway with protein folding and a 
defense mechanism of the cell in response to deregulated protein homeostasis
182,183
. All 
these factors have to be balanced against possible toxicity gains resulting from reduced 
amounts of amyloid fibrils.  
4.5 Conclusions 
Originally derived based on generic phase transition principles of supersaturation-
driven nucleation and growth, the CLM is now ready to address OPA as an important 
peculiarity of amyloid fibril formation determining toxicological aspects of protein 
aggregation. This theoretical framework predicts that OPA directly reduces the formation 
of amyloid fibrils, a consequence that might be considered good or bad depending on 
which type of aggregates is more toxic. Off-pathway amorphous precipitates showing 
lower solubility than structured fibrils also contribute for lowering the availability of the 
amyloidogenic protein in biological media. The OPA mechanism of action involves kinetic 
and thermodynamic aspects that were thoroughly confirmed using protein depletion and 
ThT fluorescence data measured during amyloid fibril formation of HEWL. Solvation-in 
effects, here introduced to explain the shortage of soluble protein in the presence of off-
pathway aggregates, also account for variations on the apparent solubility values as 
different initial HEWL concentrations were considered and decisively contribute to 
quantitatively validate kinetic signatures of OPA such as the characteristic scaling laws of 
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the half-life coordinates. Directly influenced by solvation-in effects, the end-point amyloid 
signal is highly variable in the presence of OPA and is weakly influenced by the initial 
protein concentration. More than providing a good numerical adjustment to measured data, 
the extended CLM accounting OPA and indirect solvation effects is confirmed as a 
predictive model that needs a reduced number of parameters to anticipate multiple 
experimental outcomes. Illustrating this, the reactivation of protein aggregation observed 
after expanding the mixture volume was successfully simulated using a set of three model 
parameters previously fitted to independent kinetic data. Compatible with high-throughput 
screening methods of drug discovery, the new findings are expected to close the gap 
between in vitro and in vivo results and contribute for the design of new therapeutic 
strategies involving OPA. 
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Summary 
While the pathogenic role of aSyn amyloid fibrils is not yet clear, evidences suggest 
that intermediate species may be responsible for toxicity in the aSyn aggregation process. 
Extensive research has recently been focused in developing new inhibitors producing a 
direct or indirect effect on oligomeric species. As a result, most aggregation/toxicity 
inhibitors under study work by accelerating aggregation, removing or remodeling toxic 
oligomers or reducing fibril fragmentation, but it is not yet understood at which stages of 
oligomerization they are effective. On the other hand and remaining to be targeted, off-
pathway aggregates (OPA) suggest being important regulatory/toxic agents in aSyn 
fibrillization. A new knowledge-based strategy by using the CLM as a tool for the 
characterization of regulatory and anti-aggregation/toxicity mechanisms is presented in the 
following work. Preliminary tests of benzothiazole derivatives screening were developed 
in order to illustrate the application of this new method of analyses. Benzothiazole-2-
carbonyl chloride suggested affecting the formation of OPA. Further studies will be 
required in order to present any conclusion about its effect on aSyn fibrillization. 
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5.1 Introduction 
Alpha synuclein (aSyn) is a 140-amino acid protein encode by the SNCA gene and 
generally expressed at higth levels in neurons, in central and peripheral nervous system
184
. 
aSyn is an intrinsically disordered protein, presenting instability in its secondary and 
tertiary structure
116,185,186
. Evidences have recently suggested that aSyn in vivo may co-
exist in equilibrium as a partially folded monomer with a variety of other dynamic 
oligomeric species. Although showing stability when adopting a helically folded tetramer 
structure, as a disordered monomer and dynamic dimer aSyn tends to aggregate
187
. 
The aggregation of aSyn into amyloid fibrils, filamentous assemblies of proteins in 
which the polypeptide backbone is arranged in a characteristic cross-beta-sheet 
structure
121
, is related with a diverse group of neurodegenerative disorders known as 
synucleinopathies in which Parkinson disease (PD) is included
188
. PD is a chronic 
neurodegenerative disease characterized by the loss of dopaminergic innervation through 
death of neurons affecting one in 100 people over the age of 60
189
. In PD, deposited aSyn 
amyloid fibrils are the main component of Lewy bodies of the substantia nigra, constituting 
the second most common nerve cell pathology, after the neurofibrillary lesions of 
Alzheimer's disease
186,190
. 
Extensive research has been invested in recent years for the development of new 
therapeutic strategies for PD and other synucleinopathies. Small molecule compounds are 
considered as one of the available possibilities to inhibit protein assembly into insoluble 
amyloid aggregates and intermediated species
185
. These compounds could inhibit fibril 
aggregation by stabilizing the monomers, stabilizing the non-propagating aSyn dimmers, 
interfering with the aggregation path preventing the appearance of toxic oligomers, 
inhibiting aSyn oligomerization, preventing interactions between monomers and 
protofibrils (fibril growth inhibition), disassembling preformed fibrils and/or preventing 
amyloid-membrane interactions
31
. Although numerous aggregation inhibitors are currently 
being tested under different preclinical and clinical phases, the mechanism of action of this 
type of therapy is not completely understood. A renewed approach to drug discovery is 
needed favoring the 'in-cerebro' component and creative innovation over blind 
technology
191,192
. A knowledge-based strategy and its application are presented in this 
work by using the CLM as a tool for the characterization of anti-aggregation mechanisms. 
The central idea is to use basic principles of the physics of phase transitions on the quest of 
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new therapeutic options based on the inhibition of supramolecular assembly. High-
throughputscreens performed during the lead discovery and optimization phases are often 
reported to identify candidate aggregation inhibitors that are later dismissed during the 
expensive preclinical and clinical phases of the drug development pipeline. We ascribe 
much of this productivity shortfall to the phenomenon of apparent inhibition, i.e., non-
specific thermodynamic effects that reduce the amount of aggregates produced in-vitro but 
not in-vivo. This is because cells and tissues media are in generalmuch more buffered 
against small variations in composition than the solutions prepared in lab. Changing the 
thermodynamic activity by the addition of salts is a simple example of such interactions
130
. 
Hits having specific aggregation-rate lowering effects are promising lead compounds and 
deserve further investment. Impressive as they may seem, results showing decreased 
amounts of produced aggregates should be handled with care especially if they result from 
indiscriminate thermodynamic effects. The CLM will be able to discriminate between true 
and apparent inhibitors with the goal of identifying false positives earlier in the drug 
development pipeline
130
. Basic science is therefore used during the lead discovery phases 
in order to improve the much-lamented poor success rates on preclinical and clinical 
phases. 
However, references from PD suggest hallmark inclusions may be a protective 
mechanism developed by neurons to prevent the accumulation of the pathogenic species, 
oligomers
185,193
. 
5.2 Experimental Procedures 
5.2.1. Chemicals 
pT7-7 vector encoding for wild type (wt) α-synuclein (aSyn) was a gift from Hilal 
Lashuel (Addgene plasmid # 36046). ThT was obtained from Sigma-Aldrich (St Louis, 
MO, USA) and used as received. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
obtained from AppliChem (Darmstadt, Germany). Other materials and reagents were 
analytical grade and obtained from Sigma-Aldrich (St. Louis, MO, USA) and Merk KGaA 
(Darmstadt, Germany). 
5.2.2. Plasmid amplification, DNA purification and glycerol stocks 
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Plasmid pT7-7 aSyn wt was received as transformed bacteria in stab culture format 
(E.coli DH5α) and stored at 4ºC. Using a sterile toothpick, bacteria were streaked on a 
Luria broth (LB) agar plate containing 100 µg/ml ampicillin to grow single colonies. An 
overnight 50 ml LB liquid culture inoculated from a bacteria single colony (100 µg/ml 
ampicillin) was growth. 
A plasmid DNA isolation miniprep kit (NucleoSpin Plasmid, Macherey-Nagel 
GmbH & Co.KG., Düren, Germany) was used for plasmid DNA isolation from the 
bacterial cells. DNA was quantified spectrophotometrically at 260 nm. The purity of the 
sample was assessed by analyzing the A260/280 and the A260/230 ratios. 
Glycerol stocks were prepared since bacteria on an LB agar plate can be stored at 
4°C for no longer than a few weeks.500 µl of the overnight culture were added to 500µl of 
50% glycerol solution in 2 mL screw top tubes. Screw top tubes were gently mix, frozen in 
liquid nitrogen and stored at -80 ºC. 
5.2.3. Transformation of BL21 (DE3) E.coliwith Plasmid DNA 
BL21 (DE3) E.colicompetent cells were obtained from Labclinics (Barcelona, 
Spain) and stored at -80 ºC. Transformation of BL21 (DE3) E. colicells with plasmid DNA 
was developed using the heat shock method. 
50 ng of DNA were added to 50 µl of competent cells. After 30 minutes incubation 
on ice, the mixture of chemically competent bacteria and DNA was exposed at 42°C for 45 
s (heat shock) and then placed back on ice. Right after the addiction of 1 ml of LB 
medium, transformed cells were incubated at 37°C for 1 hour under agitation. A 
centrifugation at 13.000 rpm (room temperature) for 2 minutes was carried out and 950 µl 
of the supernatant were discarded. 100 µl of transformed bacteria were plated on a LB agar 
plate containing 100 µg/ml ampicillin and incubated overnight at 37 °C. 
5.2.4. Recombinant wt aSyn production 
BL21 (DE3) E. coli cells were transformed as explained before. An overnight 10 ml 
LB liquid culture inoculated from a bacteria single colony (100 µg/ml ampicillin) was 
growth and used to inoculate 1 l of LB medium containing 100 µg/ml ampicillin. The 1 l 
culture was incubated at 37°C with shaking (180 rpm) until the OD600 reached 0.6. 
Recombinant protein expression was induced by the addiction of 0.5 mM IPTG and 
incubated in the same conditions (37°C, shaking 180 rpm) for 4h. Bacterial cells were 
harvested by centrifugation for 20 minutes at 10,000 rpm and 4 ºC (Sorvall LYNX 6000 
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Superspeed Centrifuge and Fiberlite F12-6x500 LEX Rotor, Thermo Scientific, MA, 
USA). After removal of the supernatant, the cell pellets were frozen at -80 ºC in the 
centrifugation bottles (Nalgene, Thermo Scientific, MA, USA). 
 
5.2.5. Purification of wt aSyn 
Non chromatographic purification steps 
Under tap water, cell pellets were pushed with a spatula and transferred to a clean 
flask kept on ice. They were then resuspended in 100 ml lysis buffer (10 mM Tris·HCl pH 
8; 1 mM EDTA). The sample was divided into 10 ml volumes, kept on ice and 
ultrasonicated (Digital Sonifier Branson SLPe; 4C15, 40KHz converter) with an output 
power of 150 watts, 60 % amplitude, applied in 30 s pulses followed by a 30 s pause for a 
total ultrasonication time of 6 min. Cell debris were then pelleted by centrifugation at 
17,000 rpm in a Sorvall RC-5B centrifuge (Sorvall SS-34 Rotor, Thermo Scientific, MA, 
USA) for 20 min at 4 ºC. An ammonium sulfate precipitation step was performed by 
adding 0.166 g/ml ammonium sulfate and stirring of the solution during 1 hour at 4 ºC for 
sample homogenization. Supernatant was kept after centrifugation in the same condition as 
described before (17,000 rpm, 20 min, 4 ºC). A second ammonium precipitation step was 
performed by adding 0.129 g/ml ammonium sulfate, to selectively precipitate the aSyn 
protein. Sample was stirred for 1 hour at 4 ºC followed by centrifugation (17,000 rpm, 20 
min, 4 ºC). Supernatant was discarded and the pellet resuspended in 80-100 ml phosphate 
buffered saline (PBS). After 20 minutes of boiling at 90 ºC to denature and precipitate 
most cellular proteins, another centrifugation was carried out (17,000 rpm, 20 min, 4 ºC). 
Supernatant (containing aSyn) was kept at 4 ºC, ready for chromatographic purification 
steps. 
Chromatographic purification steps 
The supernantant obtained from the non chromatographic purification was loaded at 
5 ml/min onto a HiTrap Q HP anion exchange 5 ml column (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden), equilibrated with 50 mM phosphate buffer pH 7.4. ASyn was 
eluted around 300 mM NaCl (at 5 ml/min) by applying a linear gradient, in 50 mM 
phosphate buffer pH 7.4, over 15 column volumes. The elution fractions were analyzed by 
SDS-12% PAGE, and fractions containing aSyn (~ 17 kDa bands) were pooled and 
concentrated to 2 ml volume using 10 kDa Amicon Ultra-15 centrifugal filters (Merk 
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Millipore, Darmstadt, Germany). ASyn sample was further purified by gel filtration 
chromatography using a HiLoad 16/600 Superdex 75 prep grade column (GE Healthcare 
Bio-Sciences AB, Uppsala, Sweden) equilibrated with 50 mM phosphate buffer pH 7.4, 
200 mM NaCl. ASyn was eluted at 1 ml/min. All column chromatography was performed 
on an ÄKTA prime plus chromatography system (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden). Pure aSyn fractions were combined and concentrated to 800-1000 µl 
volume using 10 kDa Amicon Ultra-4 centrifugal filters (Merk Millipore, Darmstadt, 
Germany).Protein concentration was determined by measuring the absorbance at 275 nm 
using an extinction coefficient of 5,600 M
-1
 cm
-1
. Aliquoted protein was stored at -80 ºC 
after freezing in liquid nitrogen. 
5.2.6. Gel Electrophoresis (SDS-PAGE) and Immunoblotting 
ASyn samples were diluted in loading buffer, boiled for 5 min at 95 ºC and 
separated on 12% SDS Mini Protean TGX stain-freeprecast gels (Bio-Rad, CA, USA).Gels 
were run at 40 mA for 45min in an electrophoresis tray and visualized in a ChemiDoc 
XRS+ System (Bio-Rad, CA, USA). For blot analysis, the proteins were transfered onto 
nitrocellulose membrane (Merk Millipore, Darmstadt, Germany) using a tank blot system 
(Bio-Rad, CA, USA) and blocked overnight with 5% w/v non fat dry milk in PBS-T 
(0.01% (v/v) Tween 20 in PBS) at 4 ºC. The membrane was probed with the primary 
antibody (rabbit polyclonal antibody aSyn (C-20)-R obtained from Santa Cruz 
Biotechnology, CA, USA) at a dilution of 1:1000 for 1 h at room temperature. After 4 
PBST washes, the membrane was incubated with the secondary antibody (polyclonal goat 
anti-rabbit immunoglobulins/HRP obtained from Dako, Glostrup, Denmark) at a dilution 
of 1:5000, for 1 h at room temperature and protected from light. The immunoblot was 
finally washed 4 times with PBS-T and 4 times with PBS, incubated with Luminata 
Crescendo Western HRP Substrate (Merk Millipore, Darmstadt, Germany) and visualized 
in a ChemiDoc XRS+ System (Bio-Rad, CA, USA). 
5.2.7. Aggregation assays: ThT Fluorescence 
ThT fluorescence kinetic measurements were carry out at 37 ºC in 96-well 
microtiter microplates (Thermo Scientific, MA, USA) in a CHAMELEON 
TM
 V 
Microplate Reader (Hidex Co., Turku, Finland) at an excitation wavelength of 440 nm and 
an emission wavelength of 485 nm. ThT stock solution was prepared by dissolving the 
dried powder in 50 mM phosphate buffer pH 7.4 and filtered through a sterile 0.45 μm 
pore size PES membrane filter (Jet biofil, Seoul, Korea). The concentration was 
Chapter 5. Screening of on/off-pathway inhibition of aSyn aggregation 
 
 98 
 
determined by absorbance measurements at 411 nm using an extinction coefficient of 
22000 M
-1
cm
-1
. Samples of 120 μl, containing a 3 mm diameter glass bead per well 
(Glaswarenfabrik Karl Hecht, Sondheim, Germany), with a final ThT concentration of 70 
μM and aSyn concentration between 50 and 200 μM were sealed with 100 μl of paraffin 
oil. Measurements were recorded every 900 s, after sample homogenization by 300s 
shaking. Data were background-corrected for the ThT fluorescence of the respective 
solvent in the absence of protein. 
5.2.8. Screening of small molecule compounds: ThT Fluorescence 
ThT derivative compounds and polyphenols were first solubilized in 
dimethylsulfoxide (DMSO) to stock concentrations of 1 mM and kept at -20 ºC.  
Samples of 120 μl were prepared as described before for aggregation assays using a 
fixed protein final concentration of 140 μM and 70μM ThT. 10μl of freshly prepared 
compound solutions (obtained by dissolving the 1 mM stocks in 50 mM phosphate buffer 
pH 7.4) were added to the samples to final concentrations of 5 to 200 μM. DMSO final 
concentration did not exceed 1% (v/v). Samples were sealed with 100 μl of paraffin oil and 
measurements were recorded every 900 s, after sample homogenization by 300s shaking. 
5.3 Results and discussion 
5.3.1 Protein production 
Recombinant aSyn was produced in BL21 (DE3) E. coli cells and purified by a 
extensively used and high-yield protocol including non-chromatographic and 
chromatographic steps (see Experimental section).  
Non-chromatographic steps are based on sample boiling to remove non-aSyn 
proteins by precipitation. Since aSyn is an unfolded protein, sample boiling does not affect 
its structure, remaining in solution, while natively folded cytoplasmic proteins thermally 
denature and precipitate. 
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Figure 5.1. SDS-PAGE analysis of the aSyn non chromatographic 
purification steps. Lane 1, supernantant remaining after cell lysis. Lane 2, 
supernatant after the first ammo nium sulfate precipitation step. Lane 3, supernatant 
after the second ammonium sulfate precipitation step (aSyn is precipitated in this 
step). Lane 4, pellet after the second ammonium sulfate precipitationstep 
resuspended in PBS. Lane 5, supernatant after boiling.  
 
Figure 5.1 shows the SDS-PAGE analysis for the different steps of the non-
chromatographic purification process. The predominance of themonomeric state was 
observed. Although aSyn has a molecular mass of 14.5 kDa, it migrates on SDS-PAGE 
with an apparent mass of ~ 17 kDa as a consequence of the poor binding of its N-terminal 
acidic tail to SDS molecules
187
 (Figure 5.1). 
Chromatographic steps consisted in an ion exchange and size exclusion 
chromatography (Figure 5.2 and 5.4, respectively). The obtained yield of purified protein 
was about 10 mg/l of E. coli culture. 
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Figure 5.2. Purification of aSyn.  Anion exchange chromatography of the 
supernatant after boiling on a 5 ml HiTrap Q HP column. Absorbance is represented 
in black and conductivity in red. ASyn peak was eluted around 300 mM NaCl, 
comprising fractions from an elution volume of 68 ml until 82 ml.  
 
Aft   th         x h  g   h  m t g   hy, th      ty  f th  Sy     k’s f   t   s 
was further confirmed by SDS-PAGE (Figure 5.3) before continuing with the size 
exclusion chromatography (Figure 5.4). ASyn was eluted showing a sharp peak comprising 
from 53 to 64 ml. Fractions were also further analyzed by SDS-PAGE (Figure 5.5), 
showing bands of  ~ 17 kDa. 
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Figure 5.3. SDS-PAGE analysis of the fractions comprised in the aSyn peak 
(anion exchange chromatography, Figure 5.2). Bands of ~ 17 kDa were observed.  
 
Figure 5.4. Purification of aSyn.  Size exclusion chromatography of aSyn 
purified by previous anion exchange chromatography. Absorbance is represented in 
black and conductivity in red. The sharp peak comprising from 53 to 64 ml elution 
volume, corresponds to monomeric aSyn.  
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Figure 5.5. SDS-PAGE analysis of the fractions comprised in the monomeric 
aSyn peak (size exclusion chromatography , Figure 5.4). Bands of ~ 17 kDa were 
observed.  
 
5.3.2 ASyn aggregation kinetics  
ASyn aggregation is very sensitive to solution conditions such as temperature, pH, 
salt concentration and/or solution cofactors. The kinetics of aSyn aggregation were 
measured for 5 different aSyn initial concentrationsat pH 7.4 and 37 ºC. Experimental data 
were represented as the normalized intensity of ThT fluorescence with time (Figure 5.6A) 
and the concentration-dependent half-life coordinates (Figure 5.6B and C). Glass beads 
were used to increase agitation, promoting hydrophobic-water interfaces
116
. 
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Figure 5.6. Influence of the initial protein concentration on the kinetics of 
amyloid fibril formation of aSyn at pH 7.4 and 37 ºC. (A) ThT fluorescence increase 
during the aggregation of 50 μM (blue), 70 μM (light blue), 100 μM (green), 140 μM 
(orange) and 200 μM (red) aSyn represented in normalized units as a function of the 
incubation time. (B, C) Influence of the initial aSyn concentration (B) on the time 
A 
B 
C 
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required to reach 50% completion ( t50), log-log scale, and (C) on the aggregation 
rate at the same instant (ν50),  linear-linear scale.(B) The linear fit (dashed line) 
indicates an exponential scaling factor  of 0.72. 
 
The weak concentration dependence showed by the lag-time and the half-life 
coordinates, as well as the obtained absolute value for the scaling factor lower than 1, 
suggest the parallel formation of intermediate and off-pathway species. Obtained data of 
ThT fluorescence was represented as a function of the incubation time in order to illustrate 
the fluorescence endpoint signals, F∞ (Figure 5.7). 
 
Figure 5.7. ThT fluorescence increase during the aggregation of 50 μM 
(blue), 70 μM (light blue), 100 μM (green), 140 μM (orange) and 200 μM (red) aSyn 
represented as a function of the incubation time.  
 
The variability of the F∞ showed in Figure 5.7 is another evidence of the formation 
of intermediates and off-pathway species during aSyn amyloid fibrillization. For a 
complete qualitative analysis, log-linear representations of the measured  1   with 
the incubation time are presented (Figure 5.8). 
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Figure 5.8. The measured aggregation curves of aSyn in Figure 5.7 are 
represented in the modified coordinates (same color code as in  Figure 5.7). The 
concave phase observed for higher asyn initial concentration s suggest the existence 
of OPA. 
 
Linear trends starting after a short period of time until the end of the reaction will 
be representative of conventional hyperbolic/sigmoidal amyloid aggregation curves. The 
nonlinear concave trends during the fast growth stages are considered as atypical kinetic 
signatures, suggesting the presence of off-pathway aggregates. Additional scaling studies 
are necessary in order to consolidate this hypothesis. 
 
5.3.3 Screening of small molecule compounds 
A selection of benzothiazole derivatives was done based in the specific binding 
mode of ThT to amyloid fibrils (Table 5.1). Their chemical structure is showed in Figure 
5.9. Amyloid fibril aggregation kinetics were measured in the presence of these 
compounds for 140 μM aSyn at pH 7.4 and 37 ºC. 
The polyphenols epigallocatechin-3-gallate (EGCG) and curcumin were also 
assayed as reference inhibitors since their effect by interfering directly with amyloid fibril 
formation from several peptides and proteins had been recognize (Figure 5.9).  
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Table 5.1. List of benzothiazole derivative compounds assayed as possible 
inhibitors. 
Compound Nº Compound Name 
1 Benzothiazole 
2 Benzothiazole-2-carboxaldehyde 
3 Benzothiazole-5-carboxylic acid 
4 Ethyl benzothiazole-2-carboxylate 
5 2-(2-Aminophenyl)benzothiazole 
6 2-(4-Aminophenyl)benzothiazole 
7 2-(4-Piperidinyl)-1,3-benzothiazole 
8 2-Hydroxy-1,3-benzothiazole-6-carboxylic acid 
9 2-Methyl-1,3-benzothiazole-6-carboxylic acid 
10 4,5,6,7-Tetrahydro-1,3-benzothiazole-2-carboxylic acid 
11 Benzothiazole-2-carbonyl chloride 
12 2-(Chloromethyl)benzothiazole 
13 2-(Bromomethyl)-1,3-benzothiazole 
14 2-Chloro-1,3-benzothiazole-6-carboxylic acid 
15 6-(Hydroxymethyl)benzothiazole 
16 2-(1H-Pyrazol-3-yl)-1,3-benzothiazole 
17 2-(1H-Pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic acid 
18 2-pyrrolidin-2-yl-benzothiazole 
19 PGL-135 hydrochloride monohydrate 
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Figure 5.9. Core structure of the benzothiazole derivatives  assayed as 
possible inhibitors (names related to the numbers in  Table 5.1).  
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Figure 5.10. Core structure of polyphenols, EGCG and curcumin, assayed as 
reference inhibitors during aSyn amyloid fibrillization.  
 
On-pathway inhibition 
The impact that external factors, as small molecule compounds, can produce on 
amyloid fibrillization is attributed by the previously described CLM (Chapter 2) to kinetic 
or thermodynamic reasons. In the first case, alterations in the duration of the initial lag 
time and/or the maximum aggregation rate are observed. A specific molecular binding 
between the inhibitor and the folded protein is required to affect the rate constants for 
nucleation and/or growth. In the second case, the end plateau level of aggregation is 
affected since alterations are produced in the effective protein concentration of the system, 
although the kinetic constants will remain unchained. No specific chemical affinity is 
required for disturbing the system equilibrium and show marked effects on amyloid fibril 
formation. We call the compounds that only show a thermodynamic effect in in vitro 
 x    m  ts “       t   h b t  s”. Th s    m     s w ll b    s        s  myl    
inhibitors in later phases of the drug development process where cellular proteostasis will 
regulate the non-specific disturbances. The CLM offers a simple and practical possibility 
t      g  z  “       t”    “t   ”   h b t  s  g   st  x    m  t l   t . By f tt  g th   LM 
to experimental data through eq. 2.17 (Chapter 2), the growth and nucleation-to-growth 
rate constants are quantified.  
An example of this analysis is illustrated below for the cases of 2-(2-aminophenyl) 
benzothiazole (Figure 5.11) and EGCG (Figure 5.12). Other assayed compounds analysis 
is shown in Supplementary Information Chapter 5 (Appendix). 
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Figure 5.11. Influence of 2-(2-aminophenyl)benzothiazole  on the kinetics of 
aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 different 
compound concentrations were assayed: 5  μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). (A) ThT 
fluorescence increase represented as a function of the incubation time. (B) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. 
 
The end plateau level of aSyn aggregation seems to be affected by 2-(2-
aminophenyl)benzothiazole (Figure 5.11A). In order to analyze if any variation occurred in 
the kinetic rate constants, the obtained fibril mass increase was plotted in normalized units 
as a function of time (Figure 5.11B). No kinetic effects appear to be produced by 2-(2-
aminophenyl)benzothiazole, indicating a case of apparent inhibition. 
A 
B 
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In this preliminary test of screening of inhibitors, the assayed ThT derivative 
compounds yielded no suggestions of true inhibition on aSyn fibrillation. Contrarily, some 
cases of apparent inhibition were easily detected, following the approach illustrated as an 
example in Figure 5.11. 
When kinetic effects are observed in the representation of the normalized fibril 
mass increase, by fitting the CLM to thedata through eq 2.17 thekinetic rate constants will 
be quantified.As an example of this kind of approach, the CLM was recently used on the 
development and validation of fluorinated peptides that prevent the aggregation of 
amyloid-beta (aβ) peptide in Alzheimer's disease194. 
If fibrillization is blocked by the compound, the measured aggregation curves will 
show a linear trend instead sigmoidal profiles showingan initial lag phasefollowed by the 
subsequent exponential growth phase. EGCG and curcumin have dose-dependently shown 
to produce this effect on aSyn fibrillization
31,60
. Those compounds may bind to oligomeric 
species of aSyn, blocking interactions between aSyn and aSyn toxic oligomeric species
31
. 
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Figure 5.12. Influence of EGCG on the kinetics of aSyn amyloid fibril 
formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 different compound concentrations 
were assayed: 5 μM (light blue), 50 μM (blue), 100 μM (green) and 200 μM 
(orange). aSyn in the absence of compound (black). (A) ThT fluorescence increase 
represented as a function of the incubation time. (B) ThT fluorescen ce increase 
represented in normalized units as a function of the incubation time.  
 
Our results appear to confirm what had been previously shown in the literature
31,126
. 
Figure 5.12 illustrates the influence of different EGCG concentrations on the kinetics of 
aSyn amyloid fibril formation. Linear trends were obtained in the presence of the highest 
EGCG concentrations assayed. The lowest concentration did not appear to be enough to 
inhibit aSyn aggregation. These results allow us to classify EGCG as a true inhibitor. 
Compounds showing true inhibition effects (producing alterations in the kinetic rate 
A 
B 
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constants or completely blocking the process) will be selected for further screens. An 
increase of the success rate on the search for new inhibitory compounds will be observed 
by applying this knowledge-based strategy in high-throughput screens. 
Off-pathway regulation 
aSyn fibrillization is a process involving the formation of many different 
intermediate species and off-pathway aggregates
193
. Evidences suggest that part of the 
intermediate aggregates may be the pathogenic species, turning them one of the main 
targets of the inhibitory strategies in which extensive research has been invested
195,196
. 
EGCG and baicalein are examples of compounds producing the inhibition of aSyn 
aggregation by acting directly on the toxic oligomers
126,197
. As a consequence of this effect, 
an increase in the formation of non-toxic OPA may be produced. Special care will be 
required with compounds that block or reduce aSyn fibrillization not acting directly on the 
toxic aggregates since an increase in toxicity may be possible
195
. Other compounds 
showing dose-dependent inhibitory effects, as curcumin, seem to increase the solubility of 
aSyn monomers and affect as oligomerization as fibrillization, even its mechanism of 
action is not yet clear
31
. Alterations in OPA during the screening of inhibitors of aSyn 
fibrillization may give crucial information about the kind of inhibition and the mechanism 
of action produced by the compounds. OPA seem to act as regulatory/toxic agents in those 
specific cases of inhibition. We have applied our new CLM-tools in this preliminary test of 
benzothiazole derivatives screening in order to identify the influence that the compounds 
may have in the formation of OPA during aSyn fibrillization.  
By representing the measured  1  as a function of time in log-linear scale, the 
kinetic profilesobtained in the presence of benzothiazole derivatives were analyzed. 
Possible effects of alterations in the formation of OPA may be detected by a direct 
comparison with the profile obtained for aSyn in the absence of inhibitors. 
Results did not suggest an increase in the formation of OPA in any of the cases 
(Appendix, Supplementary Information Chapter 5). Concave profiles obtained from 
modified coordinates representation were in the same order of curvature as the one showed 
by aSyn in the absence of inhibitors. Contrarily, we found a case suggesting linear trends. 
In Figure 5.13, the influence of benzothiazole-2-carbonyl chloride on the kinetics of aSyn 
amyloid fibril formation and its representation in modified coordinates are presented. 
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Figure 5.13. Influence of benzothiazole-2-carbonyl chloride on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5μM (light blue), 50μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). (A) ThT 
fluorescence increase represented as a function of the incubation time. (B) 
Representation in modified coordinates,  1  as a function of time in log-linear  
scale.  
 
Linear trend observed in Figure 5.13B may suggest an effect of benzothiazole-2-
carbonyl chloride on intermediate and/or off-pathway species. More detailed and specific 
studies are required in order to analyze what kind of aggregates are present, their toxicity, 
and to understand the possible mechanism of action of benzothiazole-2-carbonyl chloride.  
A 
B 
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The previous analysis illustrates an example showing the simplicity and easy 
applicability presented by our new proposed method to analyze the formation of OPA. This 
new tools may help for a better understanding of the mechanism involved in the interaction 
between small molecule compounds and protein aggregates during screening of inhibitors, 
contributing as well for the clarification of the mechanism comprised in protein 
fibrillization. 
5.4 Conclusions 
With this preliminary screening of compounds we show in a simple way how to 
analyze any possible effect produced on on-pathway and off-pathway aggregation during 
amyloid fibrillization. When focusing on on-pathway aggregation, to distinguish between 
thermodynamic or kinetic effects of external factors during amyloid fibril formation will be 
crucial. Chemical compounds having a thermodynamic effect induce different reaction 
affecting the effective protein concentration of the system. Those effects are not likely to 
work in vivo as they do in vitro, being this the reason why they are considered "apparent". 
Changing the solution activity of the protein by the addition of salts is a simple example of 
such effects. "True" inhibitors, on the contrary, have some kind of specific activity by 
retarding the kinetics of nucleation and/or growth of amyloid fibrillization. The CLM 
provides the tools to discriminate between apparent and true inhibitors in the early phases 
of the drug development process, but also, in its extended form (by the addiction of the off-
pathway kinetic constant, Chapter 3), parallel nucleation steps can be characterize. We 
have also applied our new CLM-tools to detect OPA and the influence that benzothiazole 
derivatives compounds can have on it in this preliminary screening of compounds during 
aSyn fibrillization. Their potential as off-pathway modulators is shown by their effect 
attenuating or intensifying the OPA kinetic signatures. It provides a better understanding of 
the mechanism involved in the interaction between the compounds and protein aggregates 
as well as in the protein fibrillization process. This original approach for detecting and 
quantifying OPA modulators, as well as the ability to discriminate between "true and 
apparent" inhibitors, makes from the CLM a simple and easily applicable tool compatible 
with higth-throughput screening methods for drug discovery. 
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General discussion and future perspectives 
Supersaturation, key factor to drive the production of high quality protein crystals 
was previously and deeply studied by us as the driving force of this process, inspiring us in 
our decision of exploring common aspects between crystallization and amyloid 
fibrillization. In the meanwhile, an excellent paper from the group of Naiki and Goto was 
published at the end of 2011 showing the effects of ultrasounds on the promotion of 
nucleation and growth of amyloid fibrils
198
. The experimental approach followed by these 
authors was also very similar to the one that we were proposing and that was originally put 
forward by us in 2010 to crystallize proteins
5
. After this fact, and in parallel with our work, 
extensive research has been developed in the area. Not a coincidence, but a way to 
conclude the work comprised in this thesis should be consider as a high quality 
contribution to the advancement of knowledge in the in vitro amyloid aggregation 
research. 
We have used well-established concepts such as the Classical Nucleation Theory 
and size-dependent growth to describe amyloid fibril formation according to the 
"Crystallization-Like Model" (CLM), proposed by us in 2012. We found that the CLM is 
able to describe adequately all types of amyloid fibrillization kinetics identified in our 
literature survey, which included hundreds of different time-course aggregation curves. It 
is notable that the solid biophysical basis of the CLM does not compromise its final 
simplicity so that it can be understood by non-scientific audience. The model parameters 
can be simply determined from the usually available values of the time required to reach 
50% completion (t50) and of the aggregation rate at that instant (v50). While integrating the 
combined influence of seeding, nucleation, growth and fibril breakage, we are enthusiastic 
about this model which is very close to the generalized underlying principle governing the 
kinetics of amyloid fibrillization.  
As a consequence of the increasing evidences of parallel processes taking place 
during amyloid aggregation and their apparent relevance for the development of 
amyloidosis and neurodegenerative diseases, techniques and strategies to detect them in a 
simple way become essential. Since 2015, the CLM was prepared by the addition of a third 
kinetic constant, to quantitatively estimate the amount of off-pathway aggregates using no 
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additional means than the traditional amyloid-specific markers. The numerical solutions of 
the three-paramenter CLM unveil the kinetic signatures characteristic of OPA. OPA 
mechanism of action showed to involve kinetic and thermodynamic aspects, producing 
solvation-in effects that account for variations on the apparent solubility of the system 
under study. Those new findings are significantly improving the gap between in vitro and 
in vivo studies driving the effort to a more successful result. The CLM is compatible and 
ready to apply in hit-to-lead screenings of drug candidates through the in-vitro kinetic 
assay. We show as an application example our preliminary test, a starting list of ~20 
benzothiazole derivatives, candidate inhibitors of pathogenic aSyn aggregation.  
The CLM may be shortly extended to describe size distribution offering more 
detailed information about oligomerization, the different stages of the process and species 
involved, making possible to determine pathological species and the desired properties and 
mechanism of action of aggregation inhibitors: th  g  l f   “th   myloid inhibition 
       h”.  
As a result, basic science is hereby used to develop new therapeutics for 
amyloidosis and neurodegenerative diseases. We all agree that new therapeutic strategies 
may result from a better understanding of the biophysics behind neurodegenerative 
disorders. This is particularly valuable for the investigation of diseases such as 
Alzh  m  ’s, P  k  s  ’s, P         th      t   -related amyloidosis. We expect that the 
CLM may be routinely used to characterize quantitatively and qualitatively new targets for 
amyloid disease therapeutics working as a complement to other structural and molecular 
studies. 
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Discussão geral e perspectivas futuras 
Sobressaturação, factor essencial para impulsionar a produção de cristais de 
proteínas de alta qualidade foi estudado por nós anteriormente e em profundidade como a 
força diretriz deste processo, inspirando-nos na nossa decisão de explorar aspectos comuns 
entre cristalização e agregação amilóide. Enquanto isso, um excelente trabalho do grupo de 
Naiki e Goto foi publicado no final de 2011, mostrando os efeitos de ultrasons sobre a 
promoção da nucleação e crescimento de fibras de amilóide. A abordagem experimental 
seguida por estes autores foi muito semelhante ao que nos estavamos a propor e que foi 
originalmente apresentado por nós em 2010 para a cristalização proteinas . Após este facto, 
e em paralelo com o nosso trabalho, extensa investigação tem sido desenvolvida nesta área. 
Não é uma coincidência, mas sim uma maneira de concluir que o trabalho desta tese deve 
ser considerado como uma contribuição de alta qualidade para o avanço do conhecimento 
na investigação in vitro da agregação amilóide. 
Neste trabalho usamos conceitos bem estabelecidos, tais como a Teoria Classica da 
Nucleação e o crescimento dependente do tamanho para descrever a formação de fibras de 
amilóide de acordo com o "Crystalization-Like Model" (CLM), proposto por nós em 2012. 
Nós descobrimos que o CLM é capaz de descrever adequadamente todos os tipos de 
cinéticas de formação de amilóide identificados na nossa bibliografia, incluíndo centenas 
de diferentes curvas de agregação recolhidas ao longo do tempo . É notável que a sólida 
base biofísica do CLM não compromete a sua simplicidade final, de modo que pode ser 
compreendido por público não científico. Os parámetros do modelo podem ser 
simplesmente determinados a partir dos valores normalmente disponíveis do tempo 
necessário para atingir 50 % de conclusão (t50) e da taxa de agregação nesse instante (v50). 
Combinando a influência de seeding, nucleação, crescimento e fragmentação, deixa-nos 
entusiasmados por ser muito próximo do princípio fundamental geral que rege a cinética de 
formação de fibras de amilóide. 
Como consequência das crescentes evidências de processos paralelos que ocorrem 
durante a agregação amilóide e a sua aparente relevância para o desenvolvimento de 
amiloidoses e doenças neurodegenerativas, técnicas e estratégias para detectá-los de uma 
forma simples tornam-se essenciais. Desde 2015, o CLM foi preparado acrescentando uma 
terceira constante cinética, para estimar quantitativamente a quantidade de agregados off-
pathway usando nao mais do que os tradicionais marcadores específicos de amilóide. As 
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soluções numéricas do CLM com três parametros desvendaram as assinaturas 
características das cinética de agregação de OPA. Os mecanismos de ação de OPA 
mostraram envolver aspectos cinéticos e termodinâmicos, produzindo efeitos de solvation-
in, que alteram a solubilidade aparente do sistema em estudo. Estas novas descobertas 
estão a melhorar significativamente a diferença entre os estudos in vitro e in vivo fazendo 
que o esforço seja conduzido a um resultado mais bem sucedido. O CLM é compatível e 
está pronto para ser aplicado na descoberta hit-to-lead de novo fármacos através de ensaios 
cinéticos de aggregação realizados in-vitro. Neste trabalho mostramos como exemplo de 
aplicação um teste preliminar de screening de uma lista inicial de ~20 derivados de 
benzotiazol candidatos a inibidores da agregação patogénica da aSyn. 
O CLM será brevemente desenvolvido para descrever a distribuição de tamanhos 
oferecendo informação mais detalhada sobre a oligomerização, as diferentes fases do 
processo e das espécies envolvidas, tornando possível determinar espécies patológicas e as 
propriedades desejadas e mecanismos de ação dos inibidores da agregação de amilóide: a 
meta da "abordagem para a inibição amilóide". 
Como resultado, a ciência básica é usada neste trabalho para desenvolver novos 
agentes terapêuticos para doenças neurodegenerativas e amiloidoses. É consensual que 
novas estratégias terapêuticas poderão resultar de uma melhor compreensão biofísica das 
doenças neurodegenerativas. Isto é particularmente valioso para a investigação de doenças 
como Alzheimer, Parkinson, Prion ou outras amiloidoses envolvendo a agregação de 
proteínas. Espera-se que o CLM possa contribuit para a caracterizaçã quantitativa e 
qualitativa de novos alvos terapêuticos em doenças de amilóide, trabalhando como um 
complemento a outros estudos estruturais e moleculares. 
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Discusión general e perspectivas futuras 
La sobresaturación es un factor clave en la producción de cristales de proteína de 
alta calidad y estudiada previamente y en profundidad por nosotros como la fuerza motriz 
de este proceso, nos inspiró en nuestra decisión de explorar los aspectos comunes entre 
cristalización y formación de fibras de amilóide. Entre tanto, una excelente publicación del 
grupo de Naiki y Goto apareció a finales de 2011, mostrando los efectos de los 
ultrasonidos para promover la nucleación y el crecimiento de fibras deamilóide. El enfoque 
experimental seguido por estos autores fue muy similar al que nosotros estábamos 
desarrollando y que fue originalmente propuesto por nosotros en 2010 en la cristalización 
de proteínas. Después de este hecho, y en paralelo con los avances de nuestro trabajo, 
extensa investigación en esta área de estudio ha sido desarrollada. No debe ser visto como 
una coincidencia, sino como una manera de concluir que el trabajo comprendido en esta 
tesis supone una importante contribución para el avance del conocimiento en la 
investigación in vitro de la agregación amilóide. 
Hemos utilizado conceptos bien establecidos, como la Teoría Clásica de la 
Nucleación y el crecimiento dependiente del tamaño para describir la formación de fibras 
de amilóide de acuerdo con el "Crystallization-Like Model" (CLM), propuesto por 
nosotros en 2012. El CLM demostró ser capaz de describir adecuadamente todos los tipos 
de cinéticas deformación de fibras de amilóide identificados en nuestro estudio 
bibliográfico, incluyendo cientos de diferentes curvas de agregación recogidas a lo largo 
del tiempo. Es notable que la sólida base biofísica del CLM no comprometa su simplicidad 
final y pueda ser asequible incluso para la audiencia no científica. Los parámetros del 
modelo pueden ser simplemente determinados a partir de los valores generalmente 
disponibles del tiempo requerido para alcanzar el 50 % de la reacción (t50) y la velocidad 
de agregación en ese instante (v50). Combinando la influencia de “s     g”,    l    ó , 
crecimiento y fragmentación, nos entusiasma su cercanía al principio fundamental general 
que rige la cinética de formación de fibras de amilóide. 
Como consecuencia a las evidencias de la existencia de procesos de agregación 
paralelos que tienen lugar durante la agregación amilóide y su aparente relevancia en el 
desarrollo de las amiloidosis y enfermedades neurodegenerativas, el desarrollo de técnicas 
y estrategias que permitan detectarlos de manera sencilla se ha convertido en un objetivo 
esencial. Desde 2015, modificaciones en el CLM fueron realizadas mediante la adición de 
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una tercera constante cinética, permitiendo estimar cuantitativamente la cantidad de 
agregados off-pathwaymediante los métodos tradicionales de uso de marcadores de 
amilóide específicos. Las soluciones numéricas del CLM de tres parametros revelan la 
firma cinética característica de OPA. El mecanismo de acción de OPA mostró involucrar 
aspectos cinéticos y termodinámicos, produciendo efectos de exclusión molecular que 
afectan la solubilidad aparente del sistema en estudio. Estos nuevos hallazgos mejorarán 
significativamente el abismo entre los estudios in vitro e in vivo, conduciendo el esfuerzo a 
un resultado más exitoso. El CLM es compatible y está listo para ser aplicado en “hit-to-
l    s       gs” de candidatos a fármacos a través del seguimiento de cinéticas de 
agregación in vitro. Mostramos como un ejemplo de aplicación nuestro estudio preliminar, 
una lista inicial de ~20 derivados del benzotiazol, como candidatos a inhibidores de la 
agregación de aSyn patógena. 
El CLM será próximamente extendido para comprender distribución de tamaños, 
ofreciendo de este modo información más detallada acerca de las diferentes especies 
involucradas en el proceso, así como de sus diferentes etapas. Esto hará posible determinar 
las especies patológicas y las propiedades deseadas y el mecanismo de acción de los 
inhibidores de la agregación: el principal objetivo del "panorama amilóide". 
Como resultado, la ciencia básica es utilizada en este trabajo para el desarrollo de 
nuevas herramientas terapéuticas para las amiloidosis y enfermedades neurodegenerativas. 
Todos estamos de acuerdo en que las nuevas estratégias terapéuticas pueden ser el 
resultado de una mejor comprensión de los procesos biofísicos detrás de las enfermedades 
neurodegenerativas. Esto es particularmente valioso para la investigación de enfermedades 
como Alzheimer, Parkinson, Prion u otras amiloidosis relacionadas con la agregación de 
proteínas. Esperamos que el CLM se utilice de forma rutinaria para caracterizar 
cuantitativa y cualitativamente nuevos objetivos para terapias de enfermedades de 
amilóide, trabando como complemento a otros estudios estructurales y moleculares. 
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Screening of on/off-pathway inhibition of aSyn aggregation 
Amyloid fibril aggregation kinetics (140 μM aSyn at pH 7.4 and 37 ºC) were 
measured in the presence of a selection of benzothiazole derivatives and the polyphenols 
epigallocatechin-3-gallate (EGCG) and curcumin. The obtained data and corresponding 
analysis are shown bellow. 
 
1. Benzothiazole 
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Figure App.1. Influence of benzothiazole on the kinetics of aSyn amyloid 
fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different compound 
concentrations were assayed: 5 μM (light blue), 50 μM (blue), 100 μM (green) and 
200 μM (orange). aSyn in the absence of compound (black). (Top) ThT fluorescence 
increase represented as a function of the incubation time. (Middle) ThT fluorescence 
increase represented in normalized units as a function of the incubation time . 
(Bottom) Representation in modified coordinates,  as a function of time in 
log-linear scale.  
 
2. Benzothiazole-2-carboxaldehyde 
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Figure App.2. Influence of benzothiazole-2-carboxaldehyde on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). ( Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
3. Benzothiazole-5-carboxylic acid 
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Figure App.3. Influence of benzothiazole-5-carboxylic acid on the kinetics of 
aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). (Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
4. Ethyl benzothiazole-2-carboxylate 
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Figure App.4. Influence of ethyl benzothiazole-2-carboxylate on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). ( Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
5. 2-(2-Aminophenyl)benzothiazole 
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Figure App.5. Influence of 2-(2-aminophenyl)benzothiazole  on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). (Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
  
6. 2-(4-Aminophenyl)benzothiazole 
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Figure App.6. Influence of 2-(4-aminophenyl)benzothiazole on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). ( Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
7. 2-(4-Piperidinyl)-1,3-benzothiazole 
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Figure App.7. Influence of 2-(4-piperidinyl) -1,3-benzothiazole on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
8. 2-Hydroxy-1,3-benzothiazole-6-carboxylic acid 
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Figure App.8. Influence of 2-hydroxy-1,3-benzothiazole-6-carboxylic acid  on 
the kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
9. 2-Methyl-1,3-benzothiazole-6-carboxylic acid 
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Figure App.9. Influence of ethyl 2-methyl-1,3-benzothiazole-6-carboxylic 
acid on the kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 
ºC). 4 different compound concentrations were assayed: 5 μM (light blue), 50 μM 
(blue), 100 μM (green) and 200 μM (orange). aSyn in the absence of compound 
(black). (Top) ThT fluorescence increase represented as a function of the incubation 
time. (Middle) ThT fluorescence increase represented in normalized units as a 
function of the incubation time. (Bottom) Representation in modified coordinates,  
as a function of time in log-linear scale.  
 
10. 4,5,6,7-Tetrahydro-1,3-benzothiazole-2-carboxylic 
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Figure App.10. Influence of ethyl 4,5,6,7-tetrahydro-1,3-benzothiazole-2-
carboxylic on the kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 
and 37 ºC). 4 different compound concentrations were assayed: 5 μM (light blue), 50 
μM (blue), 100 μM (green) and 200 μM (orange). aSyn in the absence of compound 
(black). (Top) ThT fluorescence increase represented as a function of the incubation 
time. (Middle) ThT fluorescence increase represented in normalized units as a 
function of the incubation time . (Bottom) Representation in modified coordinates,  
as a function of time in log-linear scale.  
 
11. Benzothiazole-2-carbonyl chloride 
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Figure 5.11. Influence of benzothiazole-2-carbonyl chloride on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). ( Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
12. 2-(Chloromethyl)benzothiazole 
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Figure App.12. Influence of ethyl 2-(chloromethyl)benzothiazole  on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates,  as a 
function of time in log-linear scale.  
 
13. 2-(Bromomethyl)-1,3-benzothiazole 
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Figure App.13. Influence of ethyl 2-(bromomethyl)-1,3-benzothiazole on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
14. 2-Chloro-1,3-benzothiazole-6-carboxylic acid 
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Figure App.14. Influence of ethyl 2-chloro-1,3-benzothiazole-6-carboxylic 
acid on the kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 
ºC). 4 different compound concentrations were assayed: 5 μM (light blue), 50 μM 
(blue), 100 μM (green) and 200 μM (orange). aSyn in the absence of compound 
(black). (Top) ThT fluorescence increase represented as a function of the incubation 
time. (Middle) ThT fluorescence increase represented in normalized units as a 
function of the incubation time . (Bottom) Representation in modified coordinates,  
as a function of time in log-linear scale.  
 
15. 6-(Hydroxymethyl)benzothiazole 
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Figure App.15. Influence of ethyl 6-(hydroxymethyl)benzothiazole  on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation t ime. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
16. 2-(1H-Pyrazol-3-yl)-1,3-benzothiazole 
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Figure App.16. Influence of 2-(1H-pyrazol-3-yl)-1,3-benzothiazole on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
17. 2-(1H-Pyrrol-1-yl)-1,3-benzothiazole-6-carboxylic 
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Figure App.17. Influence of 2-(1H-pyrrol-1-yl)-1,3-benzothiazole-6-
carboxylic on the kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 
and 37 ºC). 4 different compound concentrations were assayed: 5 μM (light blue), 50 
μM (blue), 100 μM (green) and 200 μM (orange). aSyn in the absence of compound 
(black). (Top) ThT fluorescence increase represented as a function of the incubation 
time. (Middle) ThT fluorescence increase represented in normalized units as a 
function of the incubation time . (Bottom) Representation in modified coordinates,  
as a function of time in log-linear scale.  
 
18. 2-pyrrolidin-2-yl-benzothiazole 
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Figure App.18. Influence of 2-pyrrolidin-2-yl-benzothiazole on the kinetics 
of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 different 
compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  100 μM 
(green) and 200 μM (orange). aSyn in the absence of compound (black). ( Top) ThT 
fluorescence increase represented as a function of the incubation time . (Middle) ThT 
fluorescence increase represented in normalized units as a function of the incubation 
time. (Bottom) Representation in modified coordinates, as a function of 
time in log-linear scale.  
 
19. PGL-135 hydrochloride monohydrate 
 
Figure App.19. Influence of PGL-135 hydrochloride monohydrate  on the 
kinetics of aSyn amyloid fibril formation (aSyn 140 μM, pH 7.4 and 37 ºC) . 4 
different compound concentrations were assayed: 5 μM (light blue), 50 μM (blue),  
100 μM (green) and 200 μM (orange). aSyn in the absence of compound (black). 
(Top) ThT fluorescence increase represented as a function of the incubation time. 
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(Middle) ThT fluorescence increase represented in normalized units as a function of 
the incubation time. (Bottom) Representation in modified coordinates, as a 
function of time in log-linear scale.  
 
20. Epigallocatechin-3-gallate (EGCG) 
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Figure App.20. Influence of EGCG on the kinetics  of aSyn amyloid fibril 
formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 different compound concentrations 
were assayed: 5 μM (light blue), 50 μM (blue), 100 μM (green) and 200 μM 
(orange). aSyn in the absence of compound (black). ( Top) ThT fluorescence increase 
represented as a function of the incubation time. (Middle) ThT fluorescence increase 
represented in normalized units as a function of the incubation time . (Bottom) 
Representation in modified coordinates, as a function of time in log-linear 
scale.  
 
21. Curcumin 
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Figure App.21. Influence of curcumin on the kinetics of aSyn amyloid fibril 
formation (aSyn 140 μM, pH 7.4 and 37 ºC). 4 different compound concentrations 
were assayed: 5 μM (light blue), 50 μM (blue), 100 μM (green) and 200 μM 
(orange). aSyn in the absence of compound (black). ( Top) ThT fluorescence increase 
represented as a function of the incubation time. (Middle) ThT fluorescence increase 
represented in normalized units as a function of the incubation time . (Bottom) 
Representation in modified coordinates, as a function of time in log-linear 
scale.
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